SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,_BIVALIRUDIN,ST ELEVATION MYOCARDIAL INFARCTION,NCT03822975,Not Applicable,0.090870398472526,0.909129601527474
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE,BULIMIA NERVOSA,NCT04225221,Phase 2,0.059417752714857164,0.940582247285143
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.1009553980836582,0.8990446019163417
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_PROGESTERONE,BULIMIA NERVOSA,NCT04225221,Phase 2,0.04345834061692158,0.9565416593830786
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_PROGESTERONE,CANNABIS USE,NCT03729869,Phase 2,0.043635352887384765,0.9563646471126154
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_PROGESTERONE,TRAUMATIC BRAIN INJURY,NCT04426487,Early Phase 1,0.023011063886961468,0.9769889361130384
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,BULIMIA NERVOSA,NCT04225221,Phase 2,0.030451335229321544,0.9695486647706784
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,URINARY TRACT INFECTIONS,NCT04301934,Not Applicable,0.007656286925310178,0.99234371307469
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,ANOREXIA NERVOSA,NCT04021017,Phase 1,0.01679855005945147,0.9832014499405486
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,_ESTRADIOL,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|SCHIZOPHRENIFORM DISORDERS,NCT04093518,Phase 3,0.004030280803555275,0.9959697191964448
CC(=O)[O-],_ACETATE,BULIMIA NERVOSA,NCT04225221,Phase 2,0.10644750915229366,0.8935524908477062
CC(=O)[O-],_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.015747296642857875,0.9842527033571422
CC(=O)[O-],_ACETATE,HERPES ZOSTER,NCT04258930,Not Applicable,0.013287747514272443,0.9867122524857276
CC(=O)[O-],_ACETATE,DEPRESSION,NCT02837432,Early Phase 1,0.07793375795637943,0.9220662420436204
CC(=O)[O-],_ACETATE,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT04002934,Phase 2,0.021128611289097127,0.9788713887109028
CC(=O)[O-],_ACETATE,HIV-1 INFECTION,NCT03536234,Phase 2,0.023945102046364783,0.9760548979536354
CC(=O)[O-],_ACETATE,BURN,NCT01413620,Phase 1,0.033182655994950634,0.9668173440050496
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE_ACETATE,BULIMIA NERVOSA,NCT04225221,Phase 2,0.1831839436965166,0.8168160563034834
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,_LEUPROLIDE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.1712684149169557,0.8287315850830442
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.03694272035508192,0.9630572796449179
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,_GOSERELIN,BREAST NEOPLASM,NCT01723774,Phase 2,0.1289720474397973,0.8710279525602027
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,_FULVESTRANT,NEOPLASMS,NCT02530411,Phase 2,0.18726014890162293,0.8127398510983768
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.1258197940212969,0.8741802059787028
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,BRAIN TUMOR,NCT03122197,Early Phase 1,0.2697963609609739,0.7302036390390261
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.02484373518990106,0.9751562648100988
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,FRONTOTEMPORAL DEMENTIA,NCT04408625,Phase 1|Phase 2,0.046460975692824764,0.9535390243071752
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.046460975692824764,0.9535390243071752
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,_ABIRATERONE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.18325541439621268,0.8167445856037874
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,_ABIRATERONE_ACETATE,PROSTATIC NEOPLASMS,NCT03007732,Phase 2,0.27869564035946426,0.7213043596405359
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASMS,NCT03693612,Phase 2,0.7793269079018303,0.2206730920981698
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.6516871482546175,0.34831285174538257
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,_DOCETAXEL,NEOPLASM METASTASIS,NCT00781612,Phase 2,0.7777843338927733,0.22221566610722665
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,_TRIPTORELIN,HIV-1 INFECTION,NCT03536234,Phase 2,0.3099323278198595,0.6900676721801406
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,GASTRIC CANCER,NCT04178460,Phase 1,0.2434375094043313,0.7565624905956689
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.2304212567077224,0.7695787432922776
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.21637404981014607,0.783625950189854
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,METASTATIC MELANOMA,NCT03925350,Phase 2,0.2488407327918677,0.7511592672081325
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACYCLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.1863569414526891,0.8136430585473109
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,_VALACICLOVIR,PROSTATE CANCER,NCT01436968,Phase 3,0.1863569414526891,0.8136430585473109
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,PROSTATIC NEOPLASMS,NCT03834519,Phase 3,0.39202616706016735,0.6079738329398328
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.2446182160037935,0.7553817839962066
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.30791102083854993,0.6920889791614502
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.44861804014724266,0.5513819598527574
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.3860261193512857,0.6139738806487142
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.3018246225179764,0.6981753774820237
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,METASTATIC MELANOMA,NCT03475134,Phase 1,0.3342711915864819,0.6657288084135179
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,CANCER,NCT02574728,Phase 2,0.3898107579390233,0.6101892420609767
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.3898107579390233,0.6101892420609767
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,HEPATOCELLULAR CARCINOMA,NCT04011033,Phase 2|Phase 3,0.13148342776564806,0.8685165722343521
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,RETINOBLASTOMA,NCT02870907,Phase 2,0.20992809388827866,0.7900719061117212
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.3898107579390233,0.6101892420609767
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,MULTIPLE SCLEROSIS,NCT03477500,Phase 3,0.0994265047776246,0.9005734952223753
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.029873564196931258,0.9701264358030688
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.10782047423727953,0.8921795257627206
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.11849085735199034,0.8815091426480097
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,LYMPHEDEMA,NCT04390685,Phase 1|Phase 2,0.07315853345508586,0.9268414665449142
CS(=O)(=O)OCCCCOS(C)(=O)=O,_BUSULFAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.6275324059666422,0.3724675940333579
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.4370597385523169,0.5629402614476829
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.4756829717314257,0.5243170282685744
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,METASTATIC MELANOMA,NCT03475134,Phase 1,0.4308421901257564,0.5691578098742437
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.488066132000447,0.511933867999553
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,HEPATOCELLULAR CARCINOMA,NCT02905188,Phase 1,0.4942369582576302,0.5057630417423699
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.5483442210986088,0.4516557789013912
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,HEPATOCELLULAR CARCINOMA,NCT04411706,Phase 2,0.4245991475258799,0.5754008524741202
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,_CAPECITABINE,QUALITY OF LIFE,NCT03577392,Phase 2|Phase 3,0.6979347691175619,0.3020652308824381
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,OVARIAN CANCER,NCT03936270,Phase 2,0.35808939859089234,0.6419106014091078
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,PROSTATE CANCER,NCT02905318,Phase 2,0.3805974296127806,0.6194025703872194
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,_ANASTROZOLE,PULMONARY ARTERIAL HYPERTENSION,NCT03229499,Phase 2,0.13233558013551236,0.8676644198644878
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_EVEROLIMUS,END STAGE RENAL DISEASE,NCT03413722,,0.2373373789408537,0.7626626210591465
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,CANCER,NCT03507491,Phase 1,0.9780485518326372,0.021951448167362726
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,METASTATIC BREAST CANCER,NCT03901339,Phase 3,0.8674128158982646,0.13258718410173553
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.27778432631302546,0.7222156736869748
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,GASTRIC CANCER,NCT03801668,Phase 3,0.24510844032164786,0.7548915596783523
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASM METASTASIS,NCT00781612,Phase 2,0.3691782673051657,0.6308217326948344
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,GASTROINTESTINAL STROMAL TUMORS,NCT03944304,Phase 2,0.3150987620961666,0.6849012379038338
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_DESMOPRESSIN,"STROKE, ACUTE",NCT03696121,Phase 2,0.06892139370559314,0.9310786062944066
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_VASOPRESSIN,HYPERTENSION,NCT04170751,Not Applicable,0.13778034205277914,0.862219657947221
N=C(N)NCCC[C@H](N)C(=O)O,_ARGININE,GASTRIC CANCER,NCT01704664,Not Applicable,0.15160942781479506,0.8483905721852051
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,FRONTOTEMPORAL DEMENTIA,NCT04408625,Phase 1|Phase 2,0.0424188121492144,0.9575811878507856
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.0424188121492144,0.9575811878507856
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PNEUMONIA,NCT03852537,Phase 2,0.001655109961190168,0.9983448900388098
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PAIN MANAGEMENT,NCT03564106,Phase 2|Phase 3,0.001655109961190168,0.9983448900388098
NC[C@H](O)c1ccc(O)c(O)c1,_NOREPINEPHRINE,HYPERTENSION,NCT04170751,Not Applicable,0.048358086921222905,0.951641913078777
NC[C@H](O)c1ccc(O)c(O)c1,_NOREPINEPHRINE,GENERALIZED ANXIETY DISORDER,NCT04478526,Not Applicable,0.10442010775769213,0.8955798922423077
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,POMPE DISEASE,NCT02240407,Phase 1,0.002653696175226085,0.9973463038247741
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,"PAIN, CHRONIC",NCT02983682,Phase 3,0.028399244724732656,0.9716007552752672
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,METASTATIC MELANOMA,NCT03817125,Phase 1,0.08848419288612337,0.9115158071138768
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,ULCERATIVE COLITIS,NCT03759041,Phase 2,0.12447056800411214,0.8755294319958877
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,_VANCOMYCIN,OSTEOARTHRITIS,NCT04075526,Not Applicable,0.09115087987335124,0.9088491201266486
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,_PIPERACILLIN,APPENDICITIS,NCT02991937,Not Applicable,0.12888225330178146,0.8711177466982184
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,_AMIKACIN,"SHOCK, SEPTIC",NCT04178148,Not Applicable,0.19274415043270274,0.8072558495672972
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,_LINEZOLID,TUBERCULOUS MENINGITIS,NCT03898635,,0.5732081227405348,0.4267918772594652
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.17807852877127614,0.8219214712287238
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.3546158283171154,0.6453841716828848
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.8305613489404885,0.16943865105951178
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,RETINOBLASTOMA,NCT02870907,Phase 2,0.7243221753582172,0.2756778246417829
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.9184899122841504,0.0815100877158495
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,FRONTOTEMPORAL DEMENTIA,NCT04408625,Phase 1|Phase 2,0.1991800389186903,0.8008199610813098
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,PARKINSON'S DISEASE,NCT04127578,Phase 1|Phase 2,0.1991800389186903,0.8008199610813098
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,CANCER,NCT02574728,Phase 2,0.21429020003180835,0.785709799968192
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,SICKLE CELL DISEASE,NCT03121001,Phase 2,0.21429020003180835,0.785709799968192
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,BETA-THALASSEMIA,NCT03877809,Phase 2,0.1742806952381894,0.8257193047618111
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,DRY EYE,NCT04115800,Early Phase 1,0.06579383993123247,0.9342061600687674
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,ISCHEMIC HEART DISEASE,NCT03600961,,0.247733191484586,0.7522668085154142
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,ANGINA PECTORIS,NCT02901353,,0.247733191484586,0.7522668085154142
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,_CYTARABINE,MYELODYSPLASTIC SYNDROME,NCT03412266,Phase 2,0.2954398838035187,0.7045601161964814
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,METASTATIC MELANOMA,NCT01920516,,0.6726921828364231,0.327307817163577
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,SICKLE CELL DISEASE,NCT02766465,Phase 2,0.8172442007137914,0.1827557992862086
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.915972046467693,0.08402795353230713
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,_VERAPAMIL,ISCHEMIC STROKE,NCT03347786,Phase 1,0.1789182434678823,0.8210817565321175
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,_LEUCOVORIN,GASTRIC CANCER,NCT01924819,Phase 2|Phase 3,0.1951256629637658,0.8048743370362341
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,DEPRESSION,NCT02837432,Early Phase 1,0.01378375640817938,0.9862162435918208
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.013306292592269356,0.9866937074077308
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.0036260061217549032,0.9963739938782451
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,"SHOCK, SEPTIC",NCT03592693,Phase 2,0.0036260061217549032,0.9963739938782451
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,HIV INFECTION,NCT03237689,Early Phase 1,0.018009277447437712,0.9819907225525624
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,_ETOPOSIDE,CANCER,NCT02574728,Phase 2,0.3258512507583833,0.6741487492416165
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,PROSTATIC NEOPLASMS,NCT04034095,,0.06083445049287381,0.9391655495071259
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.001655109961190168,0.99834489003881
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,_AZATHIOPRINE,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.09496155164399736,0.9050384483560028
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.09604268324362326,0.9039573167563766
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.11082384272261901,0.889176157277381
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,TYPE 1 DIABETES,NCT03428945,Phase 2,0.1123303731166894,0.8876696268833105
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,ANALGESIA,NCT03955211,Phase 2,0.06353944283448648,0.9364605571655136
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,POMPE DISEASE,NCT02240407,Phase 1,0.01138702082195538,0.9886129791780448
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,COCAINE-RELATED DISORDERS,NCT02037126,Phase 2,0.007761014700200477,0.9922389852997996
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,_SELUMETINIB,NEUROFIBROMATOSIS TYPE 1,NCT04495127,Phase 1,0.8091774951988697,0.19082250480113072
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,MALIGNANT NEOPLASM,NCT03578081,Phase 3,0.018694623442464003,0.9813053765575358
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,CUSHING DISEASE,NCT03974789,,0.09972649050984446,0.9002735094901554
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.0372199912596186,0.9627800087403812
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,CHRONIC SHOULDER PAIN,NCT03000205,Not Applicable,0.06923059628911983,0.93076940371088
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,HYSTERECTOMY,NCT03719755,Not Applicable,0.09464098292247597,0.905359017077524
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,OSTEO ARTHRITIS OF THE KNEES,NCT03400631,Not Applicable,0.06923059628911983,0.93076940371088
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,_SOMATOSTATIN,HEPATOCELLULAR CARCINOMA,NCT02799212,Phase 3,0.19167861254618052,0.8083213874538191
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,_CABERGOLINE,ENDOMETRIOSIS,NCT03928288,Phase 2,0.10880212846870696,0.8911978715312933
CNCC[C@@H](Oc1ccccc1C)c1ccccc1,_ATOMOXETINE,"OBESITY, MORBID",NCT03460210,,0.15388309766779198,0.8461169023322079
CNCC[C@@H](Oc1ccccc1C)c1ccccc1,_ATOMOXETINE,SLEEP APNEA,NCT03919955,Phase 1|Phase 2,0.006643472842455084,0.9933565271575451
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,GASTRIC CANCER,NCT04005365,Phase 2,0.066100546413781,0.9338994535862188
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,AUTISM,NCT02428205,Not Applicable,0.013561781780726166,0.986438218219274
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,ALCOHOL DRINKING,NCT03588754,Phase 2,0.009396182878358257,0.9906038171216416
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,SHOULDER PAIN,NCT02620579,Phase 2,0.009396182878358257,0.9906038171216416
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,OBSTRUCTIVE SLEEP APNEA,NCT03049306,Phase 2,0.007056216531149242,0.9929437834688508
Clc1cccc(Cl)c1NC1=NCCN1,_CLONIDINE,PAIN MANAGEMENT,NCT02276495,Not Applicable,0.004517213657943052,0.995482786342057
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,_MODAFINIL,COCAINE-RELATED DISORDERS,NCT02896712,Phase 2,0.012442307823019562,0.9875576921769804
CC(=O)Nc1nnc(S(N)(=O)=O)s1,_ACETAZOLAMIDE,"HYPERTENSION, PULMONARY",NCT02755298,Phase 2|Phase 3,0.05929034546115775,0.9407096545388424
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,SICKLE CELL DISEASE,NCT03247218,Phase 2,0.04244652604495275,0.9575534739550472
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,AUTISM SPECTRUM DISORDER,NCT02811627,Early Phase 1,0.046560003154952255,0.9534399968450477
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY,NCT03709888,,0.14687497340239414,0.8531250265976058
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,COGNITION DISORDERS,NCT03342443,Phase 2|Phase 3,0.004136895219525555,0.9958631047804744
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MULTIPLE SCLEROSIS,NCT04035889,Not Applicable,0.010682222652904146,0.9893177773470958
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,AUTISM SPECTRUM DISORDER,NCT02487082,Phase 2,0.003991638587295645,0.9960083614127044
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,POSTOPERATIVE DELIRIUM,NCT04483596,,0.14186166921165888,0.8581383307883411
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,OBSTRUCTIVE SLEEP APNEA,NCT02484300,Not Applicable,0.04031538852334734,0.9596846114766526
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,RELAPSING REMITTING MULTIPLE SCLEROSIS,NCT03498131,Early Phase 1,0.0036260061217549032,0.9963739938782451
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,OSTEOPENIA,NCT04233112,Early Phase 1,0.0203453508406148,0.9796546491593852
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,_SERTRALINE,MYELODYSPLASTIC SYNDROME,NCT02452983,Phase 1,0.008107580670925573,0.9918924193290743
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,_SERTRALINE,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT03434041,Phase 3,0.034867354815340215,0.9651326451846596
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,DELIRIUM,NCT04456985,Not Applicable,0.04262361176185996,0.9573763882381401
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,POST OPERATIVE COGNITIVE DYSFUNCTION,NCT03485404,Not Applicable,0.05590813803014254,0.9440918619698574
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.07738404166817305,0.9226159583318271
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,AMYOTROPHIC LATERAL SCLEROSIS,NCT03427086,Phase 2,0.2631798461945425,0.7368201538054576
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,ANEMIA,NCT02757898,Phase 1,0.4144938149418201,0.58550618505818
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,_AZITHROMYCIN,BACTERIAL INFECTIONS,NCT03925480,Phase 3,0.12024082360004948,0.8797591763999503
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,_AZITHROMYCIN,INTUBATION COMPLICATION,NCT03250975,Phase 1|Phase 2,0.12426189244896604,0.8757381075510338
NC(=O)c1cccnc1,_NICOTINAMIDE,PARKINSON'S DISEASE,NCT03568968,Not Applicable,0.10171024625747628,0.8982897537425236
NC(=O)c1cccnc1,_NICOTINAMIDE,SICKLE CELL DISEASE,NCT04055818,Phase 1,0.1451490358478381,0.8548509641521618
NC(=O)c1cccnc1,_NICOTINAMIDE,HYPERTENSION,NCT04112043,Phase 1,0.14962541730533144,0.8503745826946684
NC(=O)c1cccnc1,_NICOTINAMIDE,CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY,NCT04112641,Phase 2,0.11063451105033546,0.8893654889496644
NC(=O)c1cccnc1,_NIACINAMIDE,PARKINSON'S DISEASE,NCT03568968,Not Applicable,0.10171024625747628,0.8982897537425236
NC(=O)c1cccnc1,_NIACINAMIDE,SICKLE CELL DISEASE,NCT04055818,Phase 1,0.1451490358478381,0.8548509641521618
NC(=O)c1cccnc1,_NIACINAMIDE,HYPERTENSION,NCT04112043,Phase 1,0.14962541730533144,0.8503745826946684
NC(=O)c1cccnc1,_NIACINAMIDE,CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY,NCT04112641,Phase 2,0.11063451105033546,0.8893654889496644
N#C[Fe-2](C#N)(C#N)(C#N)(C#N)N=O,_NITROPRUSSIDE,"STRESS DISORDERS, POST-TRAUMATIC",NCT02560805,Phase 2,0.3087606847766807,0.6912393152233192
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,BURN,NCT00985205,Phase 3,0.262803856112324,0.7371961438876758
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,GASTRIC CANCER,NCT01704664,Not Applicable,0.20160428581246825,0.7983957141875316
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,GENERALIZED ANXIETY DISORDER,NCT04274114,Phase 2,0.21846504184649415,0.7815349581535058
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,BURN,NCT00985205,Phase 3,0.262803856112324,0.7371961438876758
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,GASTRIC CANCER,NCT01704664,Not Applicable,0.20160428581246825,0.7983957141875316
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,GENERALIZED ANXIETY DISORDER,NCT04274114,Phase 2,0.21846504184649415,0.7815349581535058
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,_AMLODIPINE,"OBESITY, MORBID",NCT02904291,,0.2073812801730746,0.7926187198269256
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,_AMLODIPINE,CEREBRAL SMALL VESSEL DISEASE,NCT03082014,Phase 3,0.050891934677634906,0.949108065322365
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,_PERINDOPRIL,ALZHEIMER DISEASE,NCT02085265,Phase 2,0.07392146053636636,0.9260785394636336
[F-].[Na+],_SODIUM_FLUORIDE,CAROTID ARTERY STENOSIS,NCT03353103,Phase 2,0.24021603645421735,0.7597839635457827
CNC[C@H](O)c1cccc(O)c1,_PHENYLEPHRINE,"STRESS DISORDERS, POST-TRAUMATIC",NCT02560805,Phase 2,0.032615389712103704,0.9673846102878962
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.06625019580161018,0.9337498041983898
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,GLIOBLASTOMA MULTIFORME,NCT02344355,Phase 2,0.3711726072946872,0.6288273927053128
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,SEPSIS,NCT04160676,Not Applicable,0.1442785708005695,0.8557214291994303
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,DELIRIUM,NCT04214106,,0.2990116624582128,0.7009883375417875
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,_PAZOPANIB,GLIOBLASTOMA MULTIFORME,NCT02331498,Phase 1|Phase 2,0.4718234491966933,0.5281765508033067
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,GLIOMA,NCT03257618,Not Applicable,0.2189367101210671,0.7810632898789328
Cn1nnc2c(C(N)=O)ncn2c1=O,_TEMOZOLOMIDE,GLIOBLASTOMA MULTIFORME,NCT02344355,Phase 2,0.2753903812473422,0.7246096187526578
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.3244982454923121,0.675501754507688
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,GASTROINTESTINAL STROMAL TUMORS,NCT03673501,Phase 3,0.5716306255942256,0.4283693744057743
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_TEMSIROLIMUS,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.7649056709447105,0.2350943290552897
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,GASTRIC CANCER,NCT04358341,Phase 2,0.35864574237174696,0.6413542576282529
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,RETINOBLASTOMA,NCT01783535,Phase 2,0.31229132035405993,0.6877086796459402
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,METASTATIC BREAST CANCER,NCT04159818,Phase 2,0.3541839096771486,0.6458160903228517
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.7643093432765127,0.2356906567234871
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,"OBESITY, MORBID",NCT03440190,,0.08826015409099623,0.9117398459090036
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,ALCOHOL USE DISORDER,NCT03575403,Phase 1,0.0022482076868512173,0.9977517923131488
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,ANXIETY,NCT02153944,Not Applicable,0.004993936933996896,0.9950060630660029
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,LIVER CIRRHOSIS,NCT02642874,Phase 3,0.07836033479058108,0.9216396652094188
O=C([O-])[O-].[Ca+2],_CALCIUM_CARBONATE,OSTEOPOROSIS,NCT04550078,Not Applicable,0.14165561253318332,0.8583443874668165
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,_LUTEIN,PROSTATE CANCER,NCT04136353,Phase 3,0.5290762367526854,0.4709237632473144
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,_LUTEIN,GLAUCOMA,NCT03959592,Phase 1|Phase 2,0.558290392118558,0.44170960788144187
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.08175302670021564,0.9182469732997844
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.24307226038699045,0.7569277396130099
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,ULCERATIVE COLITIS,NCT02277223,Phase 3,0.0699805655923866,0.9300194344076134
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,"HEMATOMA, SUBDURAL, CHRONIC",NCT03845322,Early Phase 1,0.08574466528751126,0.9142553347124888
NCC(=O)O,_GLYCINE,MILD COGNITIVE IMPAIRMENT,NCT03493178,Early Phase 1,0.6665656759037252,0.3334343240962748
CC(=O)N[C@@H](CS)C(=O)O,_ACETYLCYSTEINE,MILD COGNITIVE IMPAIRMENT,NCT03493178,Early Phase 1,0.4102062481664874,0.5897937518335126
N[C@@H](CS)C(=O)O,_CYSTEINE,CANNABIS USE DISORDER,NCT03055377,Phase 2|Phase 3,0.19286044190806895,0.8071395580919309
CN(CC(=O)O)C(=N)N,_CREATINE,PERIPHERAL ARTERIAL DISEASE,NCT04471792,Phase 2,0.2010268059793418,0.798973194020658
CN(CC(=O)O)C(=N)N,_CREATINE,KNEE OSTEOARTHRITIS,NCT04423432,Not Applicable,0.18628990302262416,0.8137100969773756
CN(CC(=O)O)C(=N)N,_CREATINE,INTERMITTENT CLAUDICATION,NCT02993874,Not Applicable,0.18628990302262416,0.8137100969773756
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,SPINAL CORD INJURIES,NCT02323698,Phase 1|Phase 2,0.06851480148287656,0.9314851985171236
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,HIV INFECTION,NCT04425902,Phase 1,0.18326337235645,0.81673662764355
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,CROHN'S DISEASE,NCT03358706,Phase 1,0.09627141653687177,0.9037285834631282
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,CATARACT,NCT03534973,Not Applicable,0.021438310664466942,0.9785616893355328
Cn1c(=O)c2c(ncn2C)n(C)c1=O,_CAFFEINE,"PAIN, POSTOPERATIVE",NCT04280263,Not Applicable,0.03982759272987542,0.9601724072701248
N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,_TRYPTOPHAN,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|SCHIZOPHRENIFORM DISORDER,NCT04013555,Phase 1|Phase 2,0.17595954917007955,0.8240404508299202
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.06638905589253849,0.9336109441074616
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04011930,Phase 2,0.08303861420350345,0.9169613857964966
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,END STAGE RENAL DISEASE,NCT04145492,Phase 2|Phase 3,0.07666781545269286,0.9233321845473073
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,ATOPIC DERMATITIS,NCT02537509,Phase 2,0.07216722559370692,0.9278327744062932
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.0443236156208242,0.9556763843791756
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.01026083864462959,0.9897391613553704
CN(C)C(=N)NC(=N)N,_METFORMIN,FRAGILE X SYNDROME,NCT04141163,Phase 1|Phase 2,0.019825305387350483,0.9801746946126496
CN(C)C(=N)NC(=N)N,_METFORMIN,GLIOBLASTOMA MULTIFORME,NCT02780024,Phase 2,0.12337280509502264,0.8766271949049771
CN(C)C(=N)NC(=N)N,_METFORMIN,HEART FAILURE,NCT03331861,Phase 2,0.017364079738443113,0.9826359202615568
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS,NCT04068246,Early Phase 1,0.007970945487624264,0.9920290545123756
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.0300219105299435,0.9699780894700564
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.0017273316411945785,0.9982726683588056
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,SEPSIS,NCT01784159,Phase 2,0.0017273316411945785,0.9982726683588056
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.013392879143542296,0.9866071208564576
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,LIVER TRANSPLANT; COMPLICATIONS,NCT04327427,,0.13533758069716798,0.8646624193028319
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.0300219105299435,0.9699780894700564
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.0017273316411945785,0.9982726683588056
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,SEPSIS,NCT01784159,Phase 2,0.0017273316411945785,0.9982726683588056
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,MULTIPLE SCLEROSIS,NCT03824938,Phase 1|Phase 2,0.013392879143542296,0.9866071208564576
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,LIVER TRANSPLANT; COMPLICATIONS,NCT04327427,,0.13533758069716798,0.8646624193028319
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,OPIOID USE DISORDER,NCT04448561,Phase 1,0.0044392782789729355,0.9955607217210272
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,_ICOSAPENT_ETHYL,ALZHEIMER DISEASE,NCT02719327,Phase 2|Phase 3,0.17135923185872515,0.8286407681412749
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,SCHIZOPHRENIA,NCT04094207,Phase 1|Phase 2,0.06815498388174952,0.9318450161182504
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,ERECTILE DYSFUNCTION|PROSTATE CANCER,NCT03406169,Phase 3,0.20187285629736634,0.7981271437026335
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,BREAST CANCER,NCT02958852,Phase 2,0.02124099810941365,0.9787590018905864
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,"SLEEP APNEA, OBSTRUCTIVE",NCT03308578,Phase 1|Phase 2,0.01667283254223465,0.9833271674577654
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,_ATORVASTATIN,OBSTRUCTIVE SLEEP APNEA OF ADULT,NCT03122639,Early Phase 1,0.01667283254223465,0.9833271674577654
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,_VALSARTAN,"OBESITY, MORBID",NCT03535376,,0.1805249968059479,0.8194750031940521
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,PERIPHERAL ARTERIAL DISEASE,NCT03240068,Early Phase 1,0.2524879902610226,0.7475120097389774
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,RHEUMATOID ARTHRITIS,NCT03770702,Phase 3,0.1840529302986811,0.8159470697013188
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,OBESITY,NCT03777215,Early Phase 1,0.2443209470942445,0.7556790529057552
NNC(=O)c1ccncc1,_ISONIAZID,TUBERCULOUS MENINGITIS,NCT03787940,Not Applicable,0.07717923316288998,0.9228207668371098
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,_DARUNAVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.3656822417984702,0.6343177582015298
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,_DOLUTEGRAVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.36267182365972706,0.637328176340273
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,MULTIPLE SCLEROSIS,NCT03161028,Phase 2,0.10537877924635694,0.8946212207536429
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,AMYOTROPHIC LATERAL SCLEROSIS,NCT04518540,Not Applicable,0.030139054260123643,0.9698609457398762
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,"STROKE, ISCHEMIC",NCT04041167,Phase 3,0.030139054260123643,0.9698609457398762
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,GASTRIC CANCER,NCT04379596,Phase 2,0.25892229874980954,0.7410777012501903
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,BREAST CANCER,NCT02897700,Phase 1,0.2320700056522541,0.7679299943477457
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,_IRINOTECAN,GASTRIC CANCER,NCT04358341,Phase 2,0.22031357613922414,0.7796864238607759
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,HIV INFECTION,NCT04425902,Phase 1,0.21877691529146,0.78122308470854
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,NCT04284657,Phase 2,0.015857497051187937,0.984142502948812
COCCc1ccc(OCC(O)CNC(C)C)cc1,_METOPROLOL,HIV INFECTION,NCT04425902,Phase 1,0.1178220503853114,0.8821779496146885
COCCc1ccc(OCC(O)CNC(C)C)cc1,_METOPROLOL,"OBESITY, MORBID",NCT03519906,,0.11791539808554975,0.8820846019144503
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,DYSPEPSIA,NCT02621359,Phase 3,0.1298469099335852,0.8701530900664148
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,HIV INFECTION,NCT04425902,Phase 1,0.10764252084738846,0.8923574791526115
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,CROHN'S DISEASE,NCT03358706,Phase 1,0.10246609128617427,0.8975339087138257
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,_OMEPRAZOLE,GASTROESOPHAGEAL REFLUX DISEASE,NCT03367195,Phase 3,0.06811812273006385,0.9318818772699364
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,_DIGOXIN,HIV INFECTION,NCT04425902,Phase 1,0.29571443865803715,0.704285561341963
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,HIV INFECTION,NCT04425902,Phase 1,0.1530705125972407,0.8469294874027592
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.027124768573537718,0.9728752314264624
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,ALZHEIMER DISEASE,NCT03991988,Phase 2,0.02077649150406353,0.9792235084959364
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,"SLEEP APNEA, OBSTRUCTIVE",NCT03545997,Phase 3,0.0324911074959527,0.9675088925040474
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,OVARIAN HYPERSTIMULATION SYNDROME,NCT03794037,Phase 2,0.0507256473645309,0.9492743526354692
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.025479476359231885,0.9745205236407682
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.007243356619582758,0.9927566433804174
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,HIV INFECTION,NCT04425902,Phase 1,0.1009320692725008,0.899067930727499
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,CROHN'S DISEASE,NCT03358706,Phase 1,0.06734219682460629,0.9326578031753936
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,"HEPATITIS B, CHRONIC",NCT02952924,Phase 1,0.04717116500790453,0.9528288349920954
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,TOBACCO USE DISORDER,NCT03813121,Phase 1|Phase 2,0.0044392782789729355,0.995560721721027
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,POST TRAUMATIC STRESS DISORDER,NCT02727998,Phase 2,0.0044392782789729355,0.995560721721027
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,OBSESSIVE COMPULSIVE DISORDER,NCT02624596,Phase 2,0.002804078340609823,0.9971959216593902
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,"DEPRESSIVE DISORDER, MAJOR",NCT03185819,Phase 2,0.0427318867289316,0.9572681132710684
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,ACUTE POSTOPERATIVE PAIN,NCT04033471,Phase 1|Phase 2,0.002804078340609823,0.9971959216593902
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,FATIGUE,NCT04141696,Phase 1|Phase 2,0.010999291642059759,0.9890007083579404
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,_FLURBIPROFEN,HIV INFECTION,NCT04425902,Phase 1,0.15698005667618795,0.843019943323812
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],_SODIUM_CITRATE,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,NCT04284657,Phase 2,0.29616173002301066,0.7038382699769891
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,OVARIAN CANCER,NCT03532139,Phase 2,0.0677987859167074,0.9322012140832926
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_LOVASTATIN,FRAGILE X SYNDROME,NCT02998151,Phase 2,0.21024670361639733,0.7897532963836028
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,_SACUBITRIL,HYPERTROPHIC CARDIOMYOPATHY,NCT03832660,Phase 2,0.17644299582744918,0.8235570041725508
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,"OBESITY, MORBID",NCT03440177,,0.12433600545296887,0.8756639945470311
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,MYOCARDIAL INFARCTION,NCT03715998,Phase 2,0.08901444483502105,0.9109855551649788
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,"OBESITY, MORBID",NCT03460327,,0.2494341246260631,0.7505658753739368
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,MILD COGNITIVE IMPAIRMENT,NCT02646982,Phase 2,0.07966383713619281,0.9203361628638069
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_CANDESARTAN,PERIPHERAL NEUROPATHY,NCT03688633,Phase 2,0.05612219988698662,0.9438778001130133
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,_TELMISARTAN,ALZHEIMER DISEASE,NCT02085265,Phase 2,0.0982160895938452,0.9017839104061548
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_IRBESARTAN,"OBESITY, MORBID",NCT03476603,,0.2556948760041281,0.7443051239958719
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,_BUPROPION,WILSON DISEASE,NCT04526210,Phase 1,0.018456917139115004,0.981543082860885
c1cnc2cc3c(cc2n1)C1CNCC3C1,_VARENICLINE,ALCOHOL USE DISORDER,NCT04249882,Phase 2,0.0018406051383663199,0.9981593948616336
c1cnc2cc3c(cc2n1)C1CNCC3C1,_VARENICLINE,CANNABIS USE DISORDER,NCT03980561,Phase 2,0.0005391851115119439,0.9994608148884879
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,ANOREXIA NERVOSA,NCT04052568,Phase 1,0.5700776378528749,0.4299223621471252
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,COCAINE-RELATED DISORDERS,NCT02037126,Phase 2,0.8674432717272014,0.1325567282727986
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,ALCOHOL USE DISORDER,NCT04141501,Phase 2,0.6693488987043629,0.33065110129563696
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,OBSESSIVE COMPULSIVE DISORDER,NCT03356483,Phase 1,0.8674432717272014,0.1325567282727986
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,"DEPRESSIVE DISORDER, MAJOR",NCT03866174,Phase 2,0.6158738200915206,0.3841261799084794
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,CLUSTER HEADACHE,NCT02981173,Phase 1,0.7299284278751509,0.2700715721248489
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,OPIOID USE DISORDER,NCT04161066,Phase 1,0.5700776378528749,0.4299223621471252
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,MAJOR DEPRESSIVE DISORDER,NCT03554174,Phase 1,0.7299284278751509,0.2700715721248489
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,NICOTINE DEPENDENCE,NCT01943994,Not Applicable,0.8674432717272014,0.1325567282727986
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,TREATMENT RESISTANT DEPRESSION,NCT03775200,Phase 2,0.557008015753361,0.442991984246639
CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,_PSILOCYBIN,POST-TRAUMATIC HEADACHE,NCT03806985,Phase 1,0.7299284278751509,0.2700715721248489
[C-]#[O+],_CARBON_MONOXIDE,SMOKING CESSATION,NCT03059940,Early Phase 1,0.4785203191488927,0.5214796808511073
[C-]#[O+],_CARBON_MONOXIDE,ACUTE RESPIRATORY DISTRESS SYNDROME,NCT03799874,Phase 2,0.4785203191488927,0.5214796808511073
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,_BUPROPION_HYDROCHLORIDE,BINGE-EATING DISORDER,NCT03539900,Phase 2|Phase 3,0.16328843940942772,0.8367115605905723
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,_BUPROPION_HYDROCHLORIDE,WILSON DISEASE,NCT04526210,Phase 1,0.19870088059596824,0.8012991194040316
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,_HALOPERIDOL,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.016639571258146347,0.9833604287418536
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,_ESMOLOL,DIABETIC FOOT ULCER,NCT03998436,Phase 3,0.1139919167956276,0.8860080832043722
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,ALZHEIMER DISEASE,NCT04205539,Phase 1,0.008430916866268581,0.9915690831337314
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,OPIOID WITHDRAWAL,NCT04470050,Phase 1|Phase 2,0.08020557118109822,0.9197944288189016
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,_VALGANCICLOVIR,GLIOBLASTOMA MULTIFORME,NCT04116411,Phase 2,0.20808550051507846,0.7919144994849217
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,CANCER,NCT02574728,Phase 2,0.21428867613204045,0.7857113238679595
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,ANALGESIA,NCT03974932,Phase 3,0.1948735612791268,0.8051264387208732
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,_CELECOXIB,WILSON DISEASE,NCT04526197,Phase 1,0.030985020484925067,0.9690149795150748
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,_ERLOTINIB,CANCER,NCT02714530,Phase 2,0.5807779291511918,0.41922207084880825
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,"STRESS DISORDERS, POST-TRAUMATIC",NCT02560805,Phase 2,0.029901194578915262,0.9700988054210846
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,"OBESITY, MORBID",NCT03519893,,0.143305559531608,0.8566944404683919
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,CEREBRAL SMALL VESSEL DISEASE,NCT03082014,Phase 3,0.028396616642363287,0.9716033833576369
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ALZHEIMER DISEASE,NCT04063124,Phase 1|Phase 2,0.5452316705144821,0.4547683294855181
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.2656524057117229,0.7343475942882772
O=C(CCCCCCC(=O)Nc1ccccc1)NO,_VORINOSTAT,CROHN'S DISEASE,NCT03167437,Phase 1|Phase 2,0.8574212953525902,0.14257870464741018
O=C(CCCCCCC(=O)Nc1ccccc1)NO,_VORINOSTAT,REFRACTORY EPILEPSY,NCT03894826,Phase 2,0.7967294870211972,0.20327051297880327
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,_COBIMETINIB,METASTATIC MELANOMA,NCT04109456,Phase 1,0.724752862791432,0.2752471372085677
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,_PANOBINOSTAT,HIV INFECTION,NCT02471430,Phase 1|Phase 2,0.6173515752785769,0.38264842472142296
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,_REGORAFENIB,GASTRIC CANCER,NCT03627728,Phase 2,0.35207268643877265,0.6479273135612275
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,METASTATIC MELANOMA,NCT02392871,Phase 1|Phase 2,0.2780488436936222,0.7219511563063776
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,MENINGIOMA,NCT03631953,Phase 1,0.2780488436936222,0.7219511563063776
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,_DABRAFENIB,METASTATIC MELANOMA,NCT02392871,Phase 1|Phase 2,0.3773592289475524,0.6226407710524476
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,BREAST CANCER,NCT04298918,Phase 1|Phase 2,0.47725079962410294,0.5227492003758971
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,MYELODYSPLASTIC SYNDROME,NCT02942290,Phase 1,0.7235596344533818,0.2764403655466185
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,_SELINEXOR,GLIOBLASTOMA MULTIFORME,NCT04421378,Phase 1|Phase 2,0.7805258428855332,0.2194741571144669
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,PROSTATE CANCER,NCT02643667,Phase 1|Phase 2,0.7160814421006205,0.2839185578993797
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,NON-HODGKIN'S LYMPHOMA,NCT03198026,Phase 2,0.8182911150599204,0.18170888494007967
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.025455664600376324,0.9745443353996238
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,INFERTILITY,NCT03824340,Not Applicable,0.02003949370574053,0.9799605062942596
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,_CARBIDOPA,SPINAL CORD INJURIES,NCT04520178,Phase 2|Phase 3,0.03987820806941325,0.9601217919305868
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,_DROXIDOPA,ORTHOSTATIC HYPOTENSION,NCT01370512,Phase 2,0.12124707664181608,0.8787529233581839
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,_TOPIRAMATE,SCHIZOPHRENIA,NCT02808533,Not Applicable,0.018005636622861226,0.9819943633771387
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.1091956140460609,0.8908043859539391
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,ALZHEIMER DISEASE,NCT03801642,Phase 1|Phase 2,0.1091956140460609,0.8908043859539391
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,AGING,NCT04401904,Phase 1|Phase 2,0.1091956140460609,0.8908043859539391
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,PARKINSON'S DISEASE,NCT04305002,Phase 2,0.12453873204593112,0.8754612679540689
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,SMOKING CESSATION,NCT02975297,Phase 1|Phase 2,0.122589048467105,0.8774109515328948
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,ACUTE ISCHEMIC STROKE,NCT03287076,Phase 2,0.12453873204593112,0.8754612679540689
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,_DICLOFENAC,BREAST CANCER,NCT04511832,Not Applicable,0.0990721237042456,0.9009278762957544
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,_BUPRENORPHINE,"OBESITY, MORBID",NCT03460314,,0.07036791237376383,0.929632087626236
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,_CODEINE,CHRONIC HEART FAILURE,NCT04332536,Not Applicable,0.022609183518134728,0.9773908164818652
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,ANALGESIA,NCT03955211,Phase 2,0.045916396078120314,0.9540836039218796
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,"OBESITY, MORBID",NCT03476577,,0.1157657041858506,0.8842342958141494
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,_FLUCONAZOLE,CRYPTOCOCCAL MENINGITIS,NCT03945448,Phase 2|Phase 3,0.16395900042567824,0.8360409995743219
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,_CIPROFLOXACIN,PNEUMONIA,NCT03177720,Phase 1,0.11113969193180814,0.8888603080681918
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,_RITONAVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.2906273077068536,0.7093726922931464
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,_CLOBETASOL_PROPIONATE,CATARACT,NCT04249076,Phase 3,0.23499528101223416,0.765004718987766
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,_CLOBETASOL_PROPIONATE,ORAL LICHEN PLANUS,NCT04364555,Phase 2|Phase 3,0.1530000264007594,0.8469999735992405
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,INFECTION,NCT03844776,Not Applicable,0.05442066744420998,0.9455793325557901
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,PERIODONTITIS,NCT03733379,Phase 3,0.00934032686428896,0.9906596731357112
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,_DEXTROMETHORPHAN,CROHN'S DISEASE,NCT03358706,Phase 1,0.15508259584293152,0.8449174041570684
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,_DEXTROMETHORPHAN,AMYOTROPHIC LATERAL SCLEROSIS,NCT03883581,Phase 1|Phase 2,0.09982353870843937,0.9001764612915606
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,_DEXTROMETHORPHAN,CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY,NCT02271893,Phase 2,0.04978002107840476,0.9502199789215949
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,_WARFARIN,CROHN'S DISEASE,NCT03358706,Phase 1,0.07301726197237593,0.926982738027624
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,TRAUMATIC BRAIN INJURY,NCT04058132,Phase 2,0.056566138878298824,0.9434338611217012
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,MAJOR DEPRESSIVE DISORDER,NCT04344678,Not Applicable,0.019677860165502728,0.9803221398344972
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,GLAUCOMA,NCT04052269,Phase 3,0.03623062577695401,0.9637693742230459
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,ERECTILE DYSFUNCTION|PROSTATE CANCER,NCT03406169,Phase 3,0.027611978018048145,0.9723880219819516
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,BIRTH ASPHYXIA,NCT04169191,Phase 1,0.06995596393027652,0.9300440360697234
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,TRAUMATIC BRAIN INJURY,NCT04058132,Phase 2,0.1920690458658673,0.8079309541341325
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,MAJOR DEPRESSIVE DISORDER,NCT04344678,Not Applicable,0.0692336294961232,0.9307663705038768
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,BIRTH ASPHYXIA,NCT04169191,Phase 1,0.21204380613646268,0.7879561938635371
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,_CILOSTAZOL,MAJOR DEPRESSIVE DISORDER,NCT04069819,Not Applicable,0.01470958916800699,0.9852904108319929
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,_APIXABAN,"OBESITY, MORBID",NCT03448783,,0.2630404584686441,0.7369595415313558
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,_APIXABAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.0787013026319458,0.9212986973680544
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,_CALCITONIN,MIGRAINE DISORDERS,NCT04019496,,0.526765122199556,0.473234877800444
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,_PYRIMETHAMINE,MYELODYSPLASTIC SYNDROME,NCT03057990,Phase 1,0.2164578865576258,0.7835421134423745
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_CHLOROQUINE,ATRIAL FIBRILLATION,NCT02932007,Phase 2,0.11208305094458644,0.8879169490554135
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,_PROCALCITONIN,PNEUMONIA,NCT03711227,,0.7776247108614143,0.22237528913858548
C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,_DUTASTERIDE,ALCOHOL USE DISORDER,NCT04098302,Phase 2|Phase 3,0.2368378004412209,0.7631621995587792
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,PARKINSON'S DISEASE,NCT04342273,Phase 1,0.07959714692874233,0.9204028530712576
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,SCHIZOPHRENIA,NCT04369391,Phase 1,0.12597887725834794,0.8740211227416519
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.12710032070040211,0.8728996792995979
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,_IMIPENEM,PNEUMONIA,NCT03177720,Phase 1,0.20075193615101647,0.7992480638489833
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.14539262975352507,0.854607370246475
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,_TETRAC,POST-DURAL PUNCTURE HEADACHE,NCT02813655,Phase 2,0.11960161319768145,0.8803983868023185
[Cl-].[Na+],_SODIUM_CHLORIDE,CROHN'S DISEASE,NCT03681067,Phase 1|Phase 2,0.09741102222608826,0.9025889777739116
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,_CEFAZOLIN,BREAST NEOPLASM,NCT03742908,Not Applicable,0.07966937440905883,0.9203306255909413
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_BUDESONIDE,INTUBATION COMPLICATION,NCT03250975,Phase 1|Phase 2,0.05722188010973176,0.9427781198902682
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.07600351857810116,0.9239964814218988
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,INFECTION,NCT03844776,Not Applicable,0.154796083617787,0.8452039163822128
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,PERIODONTITIS,NCT03733379,Phase 3,0.07055587888642388,0.929444121113576
CN(C)C(=O)Oc1ccc[n+](C)c1,_PYRIDOSTIGMINE,ORTHOSTATIC HYPOTENSION,NCT01370512,Phase 2,0.06719359516155711,0.9328064048384428
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],_PYRIDOSTIGMINE_BROMIDE,ORTHOSTATIC HYPOTENSION,NCT01370512,Phase 2,0.1518694659706485,0.8481305340293512
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,LIVER CIRRHOSIS,NCT03005444,Not Applicable,0.001167122787812443,0.9988328772121876
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.02101182759827235,0.9789881724017276
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,_CITALOPRAM,AUTISM SPECTRUM DISORDER,NCT04145076,Not Applicable,0.039822870639029465,0.9601771293609704
CN1c2ccccc2C(NCCCCCCC(=O)O)c2ccc(Cl)cc2S1(=O)=O,_TIANEPTINE,AUTISM SPECTRUM DISORDER,NCT04145076,Not Applicable,0.10559999795942393,0.8944000020405762
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,_VENLAFAXINE,"OBESITY, MORBID",NCT03532477,,0.07456074995980985,0.92543925004019
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,_VENLAFAXINE,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT03434041,Phase 3,0.0044392782789729355,0.995560721721027
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,TYPE 1 DIABETES,NCT03228732,Early Phase 1,0.003991638587295645,0.9960083614127044
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,"OBESITY, MORBID",NCT03476525,,0.088575801300867,0.9114241986991328
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,"DEPRESSIVE DISORDER, MAJOR",NCT02709655,Phase 3,0.015825592644054073,0.984174407355946
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,_DULOXETINE,ALCOHOL USE DISORDER,NCT03575403,Phase 1,0.0044392782789729355,0.995560721721027
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,_DULOXETINE,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT03434041,Phase 3,0.0065318526983383285,0.9934681473016616
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,_DULOXETINE,DIAGNOSIS AND TREATMENT OF DEPRESSION,NCT03148522,Not Applicable,0.0044392782789729355,0.995560721721027
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,_ESCITALOPRAM,"OBESITY, MORBID",NCT03460379,,0.11632898308806235,0.8836710169119377
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,_ESCITALOPRAM,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT03434041,Phase 3,0.05366310357083968,0.9463368964291604
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,_BREXPIPRAZOLE,SCHIZOPHRENIA,NCT03874494,Phase 3,0.16878768763161844,0.8312123123683814
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,_BREXPIPRAZOLE,ALZHEIMER DISEASE,NCT03594123,Phase 3,0.2116054695580013,0.7883945304419987
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,_BREXPIPRAZOLE,ALCOHOL USE DISORDER,NCT04066192,Phase 2,0.1382698486646182,0.8617301513353817
O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,_BREXPIPRAZOLE,BORDERLINE PERSONALITY DISORDER,NCT04100096,Phase 2,0.1930365210407645,0.8069634789592355
NCC1(CC(=O)O)CCCCC1,_GABAPENTIN,"OBESITY, MORBID",NCT03476538,,0.1500545756773895,0.8499454243226106
NCC1(CC(=O)O)CCCCC1,_GABAPENTIN,AUTISM SPECTRUM DISORDER,NCT03589898,Early Phase 1,0.15808577821654254,0.8419142217834574
NCC1(CC(=O)O)CCCCC1,_GABAPENTIN,ALCOHOL USE DISORDER|BIPOLAR DISORDER,NCT03220776,Phase 2,0.03587137410322648,0.9641286258967732
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,DYSPEPSIA,NCT02621359,Phase 3,0.3387505796219188,0.6612494203780814
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,_LEVOFLOXACIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT02067780,Phase 2,0.2581919992158715,0.7418080007841286
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,_LAMOTRIGINE,"OBESITY, MORBID",NCT03497143,,0.09172288042194864,0.9082771195780514
CC(=O)NCCCS(=O)(=O)O,_ACAMPROSATE,FRAGILE X SYNDROME,NCT02998151,Phase 2,0.2536313704702937,0.7463686295297065
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,FRAGILE X SYNDROME,NCT02998151,Phase 2,0.04645406530917752,0.9535459346908224
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,HYPERTENSION,NCT02133872,Phase 1,0.04311763926167325,0.9568823607383268
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,TREATMENT RESISTANT DEPRESSION,NCT03947827,Phase 3,0.01854723813185929,0.9814527618681408
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,SCHIZOPHRENIA|SCHIZOAFFECTIVE DISORDER|SCHIZOPHRENIFORM DISORDER,NCT02533232,Phase 1,0.01854723813185929,0.9814527618681408
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,"STROKE, ISCHEMIC",NCT03320018,Phase 2|Phase 3,0.02334522803135427,0.9766547719686456
CC(C)C[C@H](CN)CC(=O)O,_PREGABALIN,ALCOHOL USE DISORDER,NCT04322305,Phase 2,0.00836762917598812,0.9916323708240118
CC(C)C[C@H](CN)CC(=O)O,_PREGABALIN,PTSD|ALCOHOL USE DISORDER,NCT02884908,Phase 3,0.017069937173816826,0.9829300628261832
CC(C)C[C@H](CN)CC(=O)O,_PREGABALIN,NAUSEA,NCT04181346,Phase 2,0.0012803730835434929,0.9987196269164564
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,PARKINSON'S DISEASE,NCT03321019,,0.21048392310091335,0.7895160768990864
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,AMYOTROPHIC LATERAL SCLEROSIS,NCT02962050,,0.21048392310091335,0.7895160768990864
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,_CAPSAICIN,SPINAL CORD INJURIES|NEUROPATHIC PAIN,NCT02441660,Not Applicable,0.08909966654615832,0.9109003334538416
NC(=O)N1c2ccccc2C=Cc2ccccc21,_CARBAMAZEPINE,TRIGEMINAL NEURALGIA,NCT03580317,Not Applicable,0.010136945881501977,0.989863054118498
NS(=O)(=O)Cc1noc2ccccc12,_ZONISAMIDE,PARKINSON'S DISEASE,NCT04182399,Not Applicable,0.08043774241542931,0.9195622575845708
NS(=O)(=O)Cc1noc2ccccc12,_ZONISAMIDE,ALCOHOL USE DISORDER,NCT02900352,Phase 1,0.07736863889421416,0.9226313611057858
CC[C@@H](C(N)=O)N1CCCC1=O,_LEVETIRACETAM,SCHIZOPHRENIA,NCT02647437,Not Applicable,0.007115137286669485,0.9928848627133304
CC[C@@H](C(N)=O)N1CCCC1=O,_LEVETIRACETAM,PARTIAL SEIZURES,NCT03340064,Phase 3,0.09131877611599423,0.9086812238840056
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,_RUFINAMIDE,LENNOX-GASTAUT SYNDROME,NCT02175173,,0.3058091043225217,0.6941908956774785
N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,_PERAMPANEL,AMYOTROPHIC LATERAL SCLEROSIS,NCT03793868,Early Phase 1,0.2042101973078123,0.7957898026921879
N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,_PERAMPANEL,ALCOHOLISM,NCT02120365,Phase 2,0.2077385164680461,0.7922614835319541
N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,_PERAMPANEL,SEIZURES,NCT04202159,,0.19329327902273627,0.8067067209772639
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,PARKINSON'S DISEASE,NCT03582137,Phase 2,0.14003331035554106,0.8599666896444589
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,ALCOHOL USE DISORDER,NCT03252756,Phase 1|Phase 2,0.15333786186732412,0.8466621381326759
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,POST TRAUMATIC STRESS DISORDER,NCT04197102,Phase 2,0.1140132912814704,0.8859867087185296
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,OPIOID USE DISORDER,NCT04192370,Phase 2,0.12190373550109455,0.8780962644989052
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,ANXIETY,NCT02548559,Phase 2,0.12190373550109455,0.8780962644989052
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,CHRONIC PAIN,NCT04044729,Early Phase 1,0.11139353853484862,0.8886064614651513
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,_CANNABIDIOL,PRADER-WILLI SYNDROME,NCT03458416,Phase 2,0.1722445450085478,0.8277554549914521
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,_OLANZAPINE,GASTRIC CANCER,NCT03575637,Phase 2,0.002339966347209013,0.9976600336527908
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,_RISPERIDONE,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.016550643186991097,0.9834493568130088
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,_ARIPIPRAZOLE,TOURETTE SYNDROME,NCT03487783,Phase 3,0.010012320486836042,0.989987679513164
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,_RISPERIDON,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.022308913243303103,0.9776910867566968
CC(C)Cn1cnc2c(N)nc3ccccc3c21,_IMIQUIMOD,METASTATIC BREAST CANCER,NCT03982004,Phase 1,0.6419966538315692,0.3580033461684306
CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,_TERBINAFINE,ULCERATIVE COLITIS,NCT02606032,Phase 2,0.10635604079041208,0.8936439592095878
CC(=O)[O-].CC(=O)[O-].[Ca+2],_CALCIUM_ACETATE,HERPES ZOSTER,NCT04258930,Not Applicable,0.06991139194349813,0.930088608056502
N[C@@H]1CONC1=O,_CYCLOSERINE,MAJOR DEPRESSIVE DISORDER,NCT03511599,Phase 1,0.3712533182436664,0.6287466817563334
Oc1ncnc2[nH]ncc12,_ALLOPURINOL,CHRONIC KIDNEY DISEASE,NCT03990363,Phase 2,0.2909364846672031,0.709063515332797
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.21759368000082624,0.7824063199991739
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.12459022061091825,0.8754097793890818
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,_ARGATROBAN,ACUTE ISCHEMIC STROKE,NCT03735979,Phase 3,0.21989507153842466,0.7801049284615753
N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,_LIOTHYRONINE,HYPOTHYROIDISM,NCT03053115,Phase 2|Phase 3,0.25886212632623684,0.7411378736737629
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,_MOMETASONE,SICKLE CELL DISEASE,NCT03758950,Phase 2,0.07585223542670103,0.9241477645732992
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,POSTOPERATIVE DELIRIUM,NCT03120442,Not Applicable,0.005,0.995
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,MALIGNANT NEOPLASM,NCT03578081,Phase 3,0.04483428352751336,0.9551657164724864
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,PONV,NCT04191694,Not Applicable,0.004993662522435098,0.995006337477565
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,"DEPRESSIVE DISORDER, MAJOR",NCT04021433,Not Applicable,0.002844375277901289,0.9971556247220988
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,FATIGUE,NCT04141696,Phase 1|Phase 2,0.008985398987164543,0.9910146010128352
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,POST-TRAUMATIC STRESS DISORDER,NCT03960658,Phase 1|Phase 2,0.016588663400940545,0.9834113365990595
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,TINNITUS,NCT03336398,Phase 2,0.003991638587295645,0.9960083614127044
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,SUBARACHNOID HEMORRHAGE,NCT02636218,Phase 2|Phase 3,0.004993760399868899,0.9950062396001309
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,CLUSTER HEADACHE,NCT04179266,Phase 1|Phase 2,0.014136023534010191,0.9858639764659898
FCOC(C(F)(F)F)C(F)(F)F,_SEVOFLURANE,ATRIAL FIBRILLATION,NCT02697448,Not Applicable,0.0046174237338212545,0.9953825762661788
FCOC(C(F)(F)F)C(F)(F)F,_SEVOFLURANE,EMERGENCE DELIRIUM,NCT04292457,Not Applicable,0.0031994603521658914,0.996800539647834
FCOC(C(F)(F)F)C(F)(F)F,_SEVOFLURANE,HEADACHE,NCT03789370,Not Applicable,0.0046174237338212545,0.9953825762661788
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,ANALGESIA,NCT03922048,Phase 2,0.01182476879926628,0.9881752312007336
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,_BUPIVACAINE,ACUTE POSTOPERATIVE PAIN,NCT04169256,Phase 1,0.01188131491043821,0.9881186850895618
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,_LIDOCAINE_HYDROCHLORIDE,HEMORRHOID,NCT03797703,Phase 1,0.03356018176678518,0.9664398182332148
CC(C)c1cccc(C(C)C)c1O,_PROPOFOL,MIGRAINE HEADACHE,NCT02485418,Not Applicable,0.029392116336219805,0.9706078836637804
CNCCC=C1c2ccccc2CCc2ccccc21,_NORTRIPTYLINE,FUNCTIONAL DYSPEPSIA,NCT03652571,Phase 3,0.007395532177398415,0.9926044678226016
CNC[C@H](O)c1ccc(O)c(O)c1,_EPINEPHRINE,PAIN MANAGEMENT,NCT02276495,Not Applicable,0.024288008063752045,0.975711991936248
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PSORIASIS,NCT04117919,Phase 2,0.002339966347209013,0.9976600336527909
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,_GUANFACINE,ALZHEIMER DISEASE,NCT03116126,Phase 3,0.04273165006059572,0.9572683499394042
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,_GUANFACINE,TRIGEMINAL NEURALGIA,NCT03865940,Phase 2,0.04910491175613129,0.9508950882438688
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,_PIROXICAM,LATERAL EPICONDYLITIS,NCT04201249,Phase 2|Phase 3,0.1173993449928214,0.8826006550071784
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,_PIROXICAM,RENAL COLIC,NCT02304783,Phase 1|Phase 2,0.1480812599031608,0.8519187400968391
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,_PIROXICAM,POSTOPERATIVE PAIN,NCT04062591,Early Phase 1,0.1480812599031608,0.8519187400968391
CN[C@]1(c2ccccc2Cl)CCCCC1=O,_ESKETAMINE,"DEPRESSIVE DISORDER, MAJOR",NCT03185819,Phase 2,0.21609757781098812,0.7839024221890117
CN[C@]1(c2ccccc2Cl)CCCCC1=O,_ESKETAMINE,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT03434041,Phase 3,0.2161531973135072,0.7838468026864928
CN[C@]1(c2ccccc2Cl)CCCCC1=O,_ESKETAMINE,BIPOLAR DEPRESSION,NCT03965871,Phase 2,0.1531174106770214,0.8468825893229786
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,_DIAZEPAM,CONTRACEPTION,NCT02799641,Not Applicable,0.012670767943690906,0.9873292320563092
O=C([O-])O.[Na+],_SODIUM_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.5364768883037738,0.4635231116962261
O=C(O)O,_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.4302889264092477,0.5697110735907523
Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,_DEXMEDETOMIDINE_HYDROCHLORIDE,POSTOPERATIVE PAIN|OPIOID USE,NCT03596424,Not Applicable,0.04395318498954892,0.9560468150104512
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.06875528477186134,0.9312447152281385
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,OBESITY,NCT03866408,Early Phase 1,0.05284873611164895,0.947151263888351
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,ALCOHOLISM,NCT03060772,Phase 2,0.05284873611164895,0.947151263888351
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,_PIOGLITAZONE,GASTROPARESIS,NCT04300127,Early Phase 1,0.11037078926484672,0.889629210735153
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,_ANTIDE,"DEPRESSIVE DISORDER, MAJOR",NCT04179006,Not Applicable,0.07992044936281027,0.9200795506371896
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,_ANTIDE,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT03434041,Phase 3,0.15149658734028554,0.8485034126597144
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,_ANTIDE,TREATMENT RESISTANT DEPRESSION,NCT03786614,Not Applicable,0.052632033523316316,0.9473679664766836
CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,_OXYBUTYNIN,SLEEP APNEA,NCT03919955,Phase 1|Phase 2,0.0571866861223287,0.9428133138776712
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,_BLEOMYCIN,GASTRIC CANCER,NCT04139070,Phase 1,0.8136885163936768,0.18631148360632324
O=S(=O)(O)CCS,_MESNA,SICKLE CELL DISEASE,NCT03263559,Phase 2,0.8741145695765699,0.1258854304234302
O=S(=O)(O)CCS,_MESNA,RETINOBLASTOMA,NCT01783535,Phase 2,0.8171174881516109,0.1828825118483889
O=S(=O)(O)CCS,_MESNA,CROHN'S DISEASE,NCT00692939,Phase 1|Phase 2,0.9833445055774804,0.016655494422519762
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,OBESITY,NCT03043053,Phase 2,0.023416097060285246,0.9765839029397148
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,AUTISM SPECTRUM DISORDER,NCT02918864,Phase 2,0.025812112773607825,0.974187887226392
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,TINNITUS,NCT04210310,Not Applicable,0.02240773564758089,0.9775922643524192
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,POSTOPERATIVE PAIN,NCT03011307,Phase 2,0.02240773564758089,0.9775922643524192
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,OPIOID USE DISORDER,NCT04051619,Phase 1,0.02240773564758089,0.9775922643524192
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,NEUROPATHIC PAIN,NCT02100956,Phase 2,0.0363429067620217,0.9636570932379782
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,BORDERLINE PERSONALITY DISORDER,NCT02225600,Not Applicable,0.036079200185826284,0.9639207998141736
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,SLEEP APNEA,NCT02564068,Early Phase 1,0.0363429067620217,0.9636570932379782
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,PRADER-WILLI SYNDROME,NCT03114371,Not Applicable,0.036329076242868456,0.9636709237571316
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,ATTENTION DEFICIT/HYPERACTIVITY DISORDER,NCT03136263,Early Phase 1,0.03551847846479922,0.9644815215352004
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,_ROCURONIUM,PROSTATE CANCER,NCT03808077,Phase 2,0.03649150305404317,0.9635084969459567
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,_KETOROLAC,ACUTE PAIN DUE TO TRAUMA,NCT04133623,Phase 3,0.01032057770310431,0.9896794222968957
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,_NALBUPHINE,POSTOPERATIVE COMPLICATIONS,NCT03470077,Phase 2,0.016865331923598226,0.9831346680764018
CCCN[C@H]1CCc2nc(N)sc2C1,_PRAMIPEXOLE,CHRONIC PAIN,NCT03842709,Early Phase 1,0.03181475975065117,0.9681852402493488
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,_MILNACIPRAN,DEPRESSION,NCT02783430,Phase 2|Phase 3,0.020581003220433068,0.979418996779567
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,_MILNACIPRAN,NEUROPATHIC PAIN,NCT01914042,Phase 2,0.020581003220433068,0.979418996779567
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,PAIN,NCT04034004,Early Phase 1,0.022540172071475847,0.977459827928524
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,EPILEPSY,NCT02332447,Phase 3,0.011979450350448778,0.9880205496495512
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,BURN,NCT03513406,Phase 3,0.003176412035662372,0.9968235879643376
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,GASTRIC CANCER,NCT04205097,Not Applicable,0.003176412035662372,0.9968235879643376
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,POSTOPERATIVE PAIN,NCT04544228,Not Applicable,0.003176412035662372,0.9968235879643376
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,_TENOFOVIR,AMYOTROPHIC LATERAL SCLEROSIS,NCT02437110,Phase 1,0.28342715213033154,0.7165728478696686
COc1cc(CC(C)N)c(OC)cc1C,_DOM,STROKE,NCT03828851,Not Applicable,0.09365861068084624,0.9063413893191538
COc1cc(CC(C)N)c(OC)cc1C,_DOM,GASTROPARESIS,NCT03810287,Early Phase 1,0.2965415845090589,0.7034584154909411
COc1cc(CC(C)N)c(OC)cc1C,_DOM,HEMOPHILIA A,NCT03818763,Phase 1,0.3080761974411722,0.6919238025588277
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,PELVIC ORGAN PROLAPSE,NCT03216083,Phase 3,0.06910277083384493,0.9308972291661552
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,"HEMATOMA, SUBDURAL, CHRONIC",NCT03582293,Phase 3,0.06991604299106294,0.9300839570089372
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,_MISOPROSTOL,LABOR PAIN,NCT03829592,Not Applicable,0.17289849194224022,0.8271015080577597
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,_VANDETANIB,NEOPLASMS,NCT02530411,Phase 2,0.4272979061208486,0.5727020938791514
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,_HYDROCHLOROTHIAZIDE,"OBESITY, MORBID",NCT03476551,,0.2027602041077666,0.7972397958922335
[Cl-].[K+],_POTASSIUM_CHLORIDE,HEART FAILURE,NCT02840799,Phase 2,0.15240676271952985,0.84759323728047
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,_BROMOCRIPTINE,OBESITY,NCT03525002,Phase 2,0.12381261615558575,0.8761873838444142
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,_GEFITINIB,CANCER,NCT02929693,Phase 3,0.7339369916039655,0.2660630083960346
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,OVARIAN CANCER,NCT03763123,Phase 1,0.7871986242380169,0.21280137576198327
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,_TOPOTECAN,RETINOBLASTOMA,NCT01783535,Phase 2,0.5445445957957571,0.4554554042042429
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,_TOLCAPONE,ALCOHOL USE DISORDER,NCT02949934,Phase 2,0.2206345770836588,0.7793654229163411
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,_TOLCAPONE,OBSESSIVE COMPULSIVE DISORDER,NCT03348930,Phase 2|Phase 3,0.12051219111190314,0.8794878088880967
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,_ATENOLOL,"STRESS DISORDERS, POST-TRAUMATIC",NCT02560805,Phase 2,0.0714415099381565,0.9285584900618437
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,_ATENOLOL,CEREBRAL SMALL VESSEL DISEASE,NCT03082014,Phase 3,0.097232505153519,0.9027674948464812
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,_TIROFIBAN,ACUTE STROKE,NCT04491695,Phase 2|Phase 3,0.15674989139171136,0.8432501086082885
CCN(CC)C(=S)SSC(=S)N(CC)CC,_DISULFIRAM,METASTATIC BREAST CANCER,NCT04265274,Phase 2,0.08169304289400307,0.9183069571059971
CCN(CC)C(=S)SSC(=S)N(CC)CC,_DISULFIRAM,GLIOBLASTOMA MULTIFORME,NCT02715609,Phase 1|Phase 2,0.09517337306901526,0.9048266269309848
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,END STAGE RENAL DISEASE,NCT03713190,Phase 2,0.19888621866014844,0.8011137813398514
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,TYPE 1 DIABETES,NCT04201496,Phase 1,0.28646906568154795,0.713530934318452
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,CHRONIC KIDNEY DISEASE,NCT03594110,Phase 3,0.2580729477315156,0.7419270522684843
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,_MARAVIROC,STROKE,NCT03172026,Phase 2|Phase 3,0.08647063499617907,0.9135293650038212
CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,_MEMANTINE_HYDROCHLORIDE,SICKLE CELL DISEASE,NCT03247218,Phase 2,0.2970851725858601,0.7029148274141399
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.056356864334277425,0.9436431356657228
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.07159147728516774,0.928408522714832
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,PULMONARY HYPERTENSION,NCT03270332,Early Phase 1,0.08354161017390323,0.9164583898260968
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,MYASTHENIA GRAVIS,NCT03914638,Phase 2|Phase 3,0.056356864334277425,0.9436431356657228
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.07159147728516774,0.928408522714832
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,PULMONARY HYPERTENSION,NCT03270332,Early Phase 1,0.08354161017390323,0.9164583898260968
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,PARKINSON'S DISEASE,NCT04164758,Phase 2,0.0013231704794605553,0.9986768295205394
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,"OBESITY, MORBID",NCT03449472,,0.09246779424446354,0.9075322057555364
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,POST TRAUMATIC STRESS DISORDER,NCT04280965,Early Phase 1,0.0013231704794605553,0.9986768295205394
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,POSTOPERATIVE DELIRIUM,NCT03739476,Phase 3,0.013882175079156006,0.9861178249208441
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,_LURASIDONE,BIPOLAR DISORDER,NCT02731612,Phase 3,0.10546302791027212,0.8945369720897278
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,_PALONOSETRON,MALIGNANT NEOPLASM,NCT03578081,Phase 3,0.3495537983128031,0.6504462016871969
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl,_ONDANSETRON_HYDROCHLORIDE,MALIGNANT NEOPLASM,NCT03578081,Phase 3,0.24517173222321045,0.7548282677767895
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.009698284776755071,0.9903017152232451
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,DIABETES MELLITUS TYPE 2,NCT04305587,Phase 1,0.042135048403753456,0.9578649515962464
COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C,_RABEPRAZOLE,INFECTIOUS DISEASES,NCT04489797,Phase 1,0.11005886409759884,0.8899411359024013
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,_CETIRIZINE,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,NCT03167216,Early Phase 1,0.12238706632037692,0.8776129336796229
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,_LACTOSE,BORDERLINE PERSONALITY DISORDER,NCT02097706,Phase 2,0.039961179793421064,0.9600388202065788
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,_CETIRIZINE_HYDROCHLORIDE,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,NCT03167216,Early Phase 1,0.4683684996260562,0.5316315003739437
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,_CROMOLYN,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,NCT03167216,Early Phase 1,0.2401823087295943,0.7598176912704058
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,_MEGESTROL_ACETATE,BREAST CANCER,NCT03306472,Phase 2,0.1226494415142325,0.8773505584857674
NCCCC[C@H](N)C(=O)O,_LYSINE,HEART FAILURE,NCT03446651,Early Phase 1,0.4809657530439294,0.5190342469560707
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,_DOBUTAMINE,MYOCARDIAL INFARCTION,NCT03289728,Not Applicable,0.17475272120315385,0.825247278796846
NCCc1c[nH]c2ccc(O)cc12,_SEROTONIN,DEPRESSION,NCT03222570,Phase 2,0.1757952865320237,0.8242047134679761
NCCc1c[nH]c2ccc(O)cc12,_SEROTONIN,GENERALIZED ANXIETY DISORDER,NCT04478526,Not Applicable,0.08558170082284088,0.9144182991771592
NCCc1c[nH]c2ccc(O)cc12,_SEROTONIN,STROKE,NCT02865642,Phase 2,0.07976494983393545,0.9202350501660644
CN1CCN2c3ncccc3Cc3ccccc3C2C1,_MIRTAZAPINE,BREAST CANCER,NCT02336750,Phase 3,0.0072769160444756936,0.9927230839555244
CN1CCN2c3ncccc3Cc3ccccc3C2C1,_MIRTAZAPINE,DIAGNOSIS AND TREATMENT OF DEPRESSION,NCT03148522,Not Applicable,0.028773117311472113,0.9712268826885276
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,_TREPROSTINIL,DIABETIC FOOT ULCER,NCT03654989,Phase 1|Phase 2,0.14857449030589884,0.8514255096941011
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,_RIOCIGUAT,SICKLE CELL DISEASE,NCT02633397,Phase 2,0.2414439250934695,0.7585560749065301
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,_EPLERENONE,HIV INFECTION,NCT02740179,Not Applicable,0.0608074130035661,0.939192586996434
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NEPHROTIC SYNDROME,NCT03750136,Not Applicable,0.8050252850656172,0.1949747149343831
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,URINARY TRACT INFECTIONS,NCT04301934,Not Applicable,0.09097183885902577,0.9090281611409742
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,ANOREXIA NERVOSA,NCT03875378,Phase 2,0.1349220052014895,0.8650779947985104
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,TRANSSEXUALISM,NCT02518009,,0.3959311319953701,0.60406886800463
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,PELVIC ORGAN PROLAPSE,NCT01648751,Not Applicable,0.1835077173735795,0.8164922826264207
CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,_AXITINIB,GASTROINTESTINAL STROMAL TUMORS,NCT04258956,Phase 2,0.5089086424646023,0.4910913575353977
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,_ALPRAZOLAM,TYPE 1 DIABETES,NCT03635437,Phase 1|Phase 2,0.0247562755245208,0.9752437244754792
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,_LOXAPINE,PSYCHOMOTOR AGITATION,NCT03513549,,0.13074987450970213,0.8692501254902978
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,BREAST CANCER,NCT02395614,Not Applicable,0.17682997229821618,0.823170027701784
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,INFECTION,NCT03844776,Not Applicable,0.14472389553049786,0.8552761044695023
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,DIABETIC FOOT ULCER,NCT03503370,Phase 2,0.2647580270409335,0.7352419729590666
COc1ccccc1OCC(O)COC(N)=O,_METHOCARBAMOL,LIVER CIRRHOSIS,NCT02642874,Phase 3,0.1154931285005737,0.8845068714994264
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,_ZOLPIDEM,PROSTATIC NEOPLASMS,NCT03436745,Phase 1,0.030658636582141432,0.9693413634178586
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,_CYPROHEPTADINE,ALCOHOL USE DISORDER,NCT04108104,Phase 2,0.02402477795816867,0.9759752220418312
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,SUBARACHNOID HEMORRHAGE,NCT04135456,Not Applicable,0.03773651485156042,0.9622634851484396
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,DIABETIC PERIPHERAL NEUROPATHY,NCT02728687,Phase 1|Phase 2,0.13651834648655,0.8634816535134499
O=NN(CCCl)C(=O)NC1CCCCC1,_LOMUSTINE,GLIOBLASTOMA MULTIFORME,NCT04421378,Phase 1|Phase 2,0.8860178671134178,0.1139821328865824
Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,_FOLINIC_ACID,AUTISM SPECTRUM DISORDER,NCT02839915,Phase 2,0.6145321310934697,0.3854678689065306
[N-]=[N+]=O,_NITROUS_OXIDE,DEPRESSION|MAJOR DEPRESSIVE DISORDER,NCT03869736,Phase 2,0.040225280265877135,0.9597747197341232
CN(C)CCCN1c2ccccc2CCc2ccccc21,_IMIPRAMINE,BREAST CANCER,NCT03122444,Early Phase 1,0.030401119148772606,0.9695988808512273
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,SICKLE CELL DISEASE,NCT03978156,Phase 1,0.039644193883188884,0.9603558061168108
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,ALZHEIMER DISEASE,NCT02792257,Phase 2,0.0441379140821565,0.9558620859178434
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,OSTEO ARTHRITIS OF THE KNEES,NCT04298528,Phase 3,0.0441379140821565,0.9558620859178434
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,CHRONIC PAIN,NCT03766269,Phase 2,0.08906377723896006,0.9109362227610396
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,BIPOLAR DISORDER,NCT04231643,Early Phase 1,0.03225150933506959,0.9677484906649304
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,_PREGNENOLONE,POST TRAUMATIC STRESS DISORDER,NCT03799562,Phase 2,0.0690191962241104,0.9309808037758894
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,_PREGNENOLONE,MAJOR DEPRESSIVE DISORDER,NCT03645096,Phase 1,0.07087142921600309,0.9291285707839968
Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,_VORTIOXETINE,"DEPRESSIVE DISORDER, MAJOR",NCT02709655,Phase 3,0.15076241954049807,0.8492375804595019
O=P([O-])([O-])O.[Na+].[Na+],_SODIUM_PHOSPHATE,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.2097213712211608,0.7902786287788391
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],_DEXAMETHASONE_SODIUM_PHOSPHATE,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.3465569820746841,0.653443017925316
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,_NABILONE,PARKINSON'S DISEASE,NCT03773796,Phase 3,0.13807788715775576,0.8619221128422442
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,_BUSPIRONE,TRAUMATIC BRAIN INJURY,NCT01821690,Not Applicable,0.01847556837148621,0.9815244316285135
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,_BUSPIRONE,SPINAL CORD INJURIES,NCT04105114,Early Phase 1,0.0722669380877369,0.9277330619122632
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,_BUSPIRONE,GASTROPARESIS,NCT03587142,Phase 2,0.03057482686817308,0.9694251731318272
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.06881291971742633,0.9311870802825736
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,_DABIGATRAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.06036526253810583,0.9396347374618942
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,_COENZYME_Q1,HUNTINGTON'S DISEASE,NCT04071639,Phase 1,0.2747056621629752,0.7252943378370247
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,_RIBAVIRIN,"HEPATITIS B, CHRONIC",NCT03759782,Phase 3,0.1339119388779414,0.8660880611220585
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,PARKINSON'S DISEASE,NCT03575195,Phase 1|Phase 2,0.04544140135955845,0.9545585986404416
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,TYPE 2 DIABETES,NCT03758144,Not Applicable,0.04446888079177305,0.9555311192082268
NC(=O)NO,_HYDROXYUREA,SICKLE CELL DISEASE,NCT04362293,Phase 2,0.4070184550064193,0.5929815449935808
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1,_LERCANIDIPINE,"OBESITY, MORBID",NCT03497156,,0.5306963913343455,0.4693036086656545
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,_LEFLUNOMIDE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.08755975810616824,0.9124402418938315
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,_NILOTINIB,DEMENTIA WITH LEWY BODIES,NCT04002674,Phase 2,0.342201994067976,0.6577980059320241
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,_NILOTINIB,HUNTINGTON'S DISEASE,NCT03764215,Phase 1,0.34471096799569706,0.6552890320043029
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.5116038642270313,0.4883961357729686
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,_TOFACITINIB,DEPRESSION|INFLAMMATION,NCT04141904,Phase 1|Phase 2,0.1844817246482655,0.8155182753517345
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,_TOFACITINIB,PSORIATIC ARTHRITIS,NCT03486457,Phase 3,0.261068439599297,0.7389315604007031
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,BURN,NCT03513406,Phase 3,0.021350193762973826,0.9786498062370262
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,GASTRIC CANCER,NCT04205097,Not Applicable,0.014659609697365326,0.9853403903026348
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,_SOLIFENACIN,OVERACTIVE BLADDER|PARKINSON DISEASE,NCT03149809,Phase 3,0.02028388135112891,0.979716118648871
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,_LACTULOSE,CROHN'S DISEASE,NCT03962998,Early Phase 1,0.16795820772211034,0.8320417922778894
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,_ENALAPRIL,"OBESITY, MORBID",NCT03460366,,0.1984066030239352,0.8015933969760648
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.05293995993976905,0.9470600400602309
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,_DOXAZOSIN,ALCOHOL USE DISORDER,NCT04135846,Phase 2,0.14207053837085648,0.8579294616291436
CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3],_GADOTERIDOL,MULTIPLE SCLEROSIS,NCT03396822,,0.24212370834714075,0.7578762916528593
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,BRAIN NEOPLASM,NCT03234309,Phase 2,0.3906902847318687,0.6093097152681313
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,CORONARY ARTERY DISEASE,NCT02954510,Phase 3,0.3414202969935329,0.6585797030064672
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,_NICARDIPINE,ANEURYSMAL SUBARACHNOID HEMORRHAGE,NCT04269408,Phase 2,0.2403644624764401,0.7596355375235597
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,_BUTORPHANOL,AGITATION,NCT03398759,Not Applicable,0.03970864633549608,0.960291353664504
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,_BUTORPHANOL,COLONOSCOPY,NCT04477733,Not Applicable,0.03970864633549608,0.960291353664504
Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,_BUTORPHAN,AGITATION,NCT03398759,Not Applicable,0.13451592669574364,0.8654840733042564
Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3,_BUTORPHAN,COLONOSCOPY,NCT04477733,Not Applicable,0.13451592669574364,0.8654840733042564
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,HYPERTENSION,NCT02425566,Phase 1,0.18615301895340064,0.8138469810465995
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,CARDIOVASCULAR DISEASE,NCT02115724,Not Applicable,0.144851145204816,0.8551488547951839
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,ATOPIC DERMATITIS,NCT03952559,Phase 3,0.3870442338317146,0.6129557661682855
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,_TRIAMCINOLONE_HEXACETONIDE,OSTEO ARTHRITIS OF THE KNEES,NCT04231318,Phase 3,0.5302744658455559,0.4697255341544439
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.007630542557643795,0.9923694574423562
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,LIVER CIRRHOSIS,NCT03995251,Not Applicable,0.02207707539231245,0.9779229246076876
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT03910738,Phase 2,0.004308806136416253,0.9956911938635836
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,SPINAL CORD INJURIES,NCT02317640,Phase 1|Phase 2,0.007630542557643795,0.9923694574423562
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,_TESTOSTERONE_CYPIONATE,PROSTATE CANCER,NCT03716739,Phase 2,0.4216227228572438,0.5783772771427562
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_ENANTHATE,PROSTATE CANCER,NCT02090114,Phase 2,0.2707734899502524,0.7292265100497477
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_UNDECANOATE,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT03910738,Phase 2,0.16150362522442185,0.8384963747755779
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_UNDECANOATE,SPINAL CORD INJURIES,NCT03576001,Phase 2,0.24335926547410225,0.7566407345258979
CCCCCCCCCCC(=O)O,_UNDECANOATE,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT03910738,Phase 2,0.2629141320898214,0.7370858679101785
CCCCCCCCCCC(=O)O,_UNDECANOATE,SPINAL CORD INJURIES,NCT03576001,Phase 2,0.35499226104446885,0.645007738955531
O=C(O)c1cccnc1,_NIACIN,POST TRAUMATIC STRESS DISORDER,NCT03752918,Phase 1,0.12024391450004596,0.8797560854999539
O=C(O)c1cccnc1,_NIACIN,OBSESSIVE COMPULSIVE DISORDER,NCT03356483,Phase 1,0.08220583647679787,0.917794163523202
O=C(O)c1cccnc1,_NIACIN,"DEPRESSIVE DISORDER, MAJOR",NCT03866174,Phase 2,0.053019534509199134,0.9469804654908008
CNC1(c2ccccc2Cl)CCCCC1=O.Cl,_KETAMINE_HYDROCHLORIDE,POSTOPERATIVE PAIN|OPIOID USE,NCT03596424,Not Applicable,0.05414585014934573,0.945854149850654
CNC1(c2ccccc2Cl)CCCCC1=O.Cl,_KETAMINE_HYDROCHLORIDE,TINNITUS,NCT03336398,Phase 2,0.16688275690208826,0.8331172430979116
CNC1(c2ccccc2Cl)CCCCC1=O.Cl,_KETAMINE_HYDROCHLORIDE,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",NCT04216888,Phase 2|Phase 3,0.2655695959431021,0.7344304040568982
OC[C@H]1O[C@H](O[C@]2(CO[C@]3(CO[C@]4(CO[C@]5(CO[C@]6(CO[C@]7(CO[C@]8(CO[C@]9(CO[C@]%10(CO[C@]%11(CO[C@]%12(CO[C@]%13(CO[C@]%14(CO[C@]%15(CO[C@]%16(CO[C@]%17(CO[C@]%18(CO[C@]%19(CO[C@]%20(CO[C@]%21(CO[C@]%22(CO[C@]%23(CO[C@]%24(CO[C@]%25(CO[C@]%26(CO[C@]%27(CO[C@]%28(CO[C@]%29(CO[C@]%30(CO[C@]%31(CO[C@]%32(CO[C@]%33(CO[C@]%34(CO[C@]%35(CO[C@]%36(CO[C@]%37(CO[C@]%38(CO)O[C@H](CO)[C@@H](O)[C@@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_INULIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04459156,Not Applicable,0.2925887159655769,0.7074112840344232
OC[C@H]1O[C@H](O[C@]2(CO[C@]3(CO[C@]4(CO[C@]5(CO[C@]6(CO[C@]7(CO[C@]8(CO[C@]9(CO[C@]%10(CO[C@]%11(CO[C@]%12(CO[C@]%13(CO[C@]%14(CO[C@]%15(CO[C@]%16(CO[C@]%17(CO[C@]%18(CO[C@]%19(CO[C@]%20(CO[C@]%21(CO[C@]%22(CO[C@]%23(CO[C@]%24(CO[C@]%25(CO[C@]%26(CO[C@]%27(CO[C@]%28(CO[C@]%29(CO[C@]%30(CO[C@]%31(CO[C@]%32(CO[C@]%33(CO[C@]%34(CO[C@]%35(CO[C@]%36(CO[C@]%37(CO[C@]%38(CO)O[C@H](CO)[C@@H](O)[C@@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_INULIN,ALCOHOLISM,NCT03803709,Not Applicable,0.22301985002744845,0.7769801499725514
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,_ADENOSINE,ACUTE STROKE,NCT03720522,,0.7093238671404924,0.2906761328595077
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,HEPATOCELLULAR CARCINOMA,NCT04258566,Phase 1,0.4093364373800283,0.5906635626199719
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,RHEUMATOID ARTHRITIS,NCT02680067,Phase 1,0.3886605403208548,0.6113394596791454
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,_INDOCYANINE_GREEN,ENDOMETRIOSIS,NCT03950206,Not Applicable,0.24485888708030604,0.755141112919694
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,_TAMSULOSIN,URINARY RETENTION,NCT03609580,Phase 1|Phase 2,0.2735771996177324,0.7264228003822677
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],_GLYCOPYRROLATE,BURN,NCT03513406,Phase 3,0.0841669472772442,0.9158330527227556
CC1CCC(C(C)C)C(O)C1,_MENTHOL,TOBACCO USE DISORDER,NCT02342327,Not Applicable,0.4561488009554436,0.5438511990445565
CC1CCC(C(C)C)C(O)C1,_MENTHOL,DIABETIC PERIPHERAL NEUROPATHY,NCT02728687,Phase 1|Phase 2,0.4991227185917401,0.5008772814082599
CC1CCC(C(C)C)C(O)C1,_MENTHOL,ACUTE PAIN,NCT04484428,Phase 2,0.5489689920590812,0.4510310079409186
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,_HYALURONATE,GLAUCOMA,NCT03758859,Not Applicable,0.3205096951195975,0.6794903048804025
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,_TICAGRELOR,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.010806873740360814,0.9891931262596392
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,_BERBERINE,METABOLIC SYNDROME,NCT03976336,Not Applicable,0.08765391001373687,0.9123460899862632
O=[N+]([O-])[O-],_NITRATE,HEART FAILURE,NCT02840799,Phase 2,0.25767256245127845,0.7423274375487218
O=[N+]([O-])[O-],_NITRATE,ERECTILE DYSFUNCTION,NCT04116060,Not Applicable,0.16886830590480265,0.8311316940951973
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,_CLAVULANIC_ACID,TOBACCO USE DISORDER,NCT03713424,Phase 2,0.15643312665327622,0.8435668733467235
OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,_BIPERIDEN,TRAUMATIC BRAIN INJURY,NCT01048138,Phase 3,0.05844611785271539,0.9415538821472846
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],_COPPER_GLUCONATE,GLIOBLASTOMA MULTIFORME,NCT02715609,Phase 1|Phase 2,0.6281008085100699,0.37189919148993
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,BREAST CANCER,NCT02788981,Phase 2,0.08459858320608042,0.9154014167939194
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,ALCOHOL USE DISORDER,NCT02989662,Not Applicable,0.12273145959514732,0.8772685404048527
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,ALCOHOL USE DISORDERS (AUD),NCT02243709,Phase 1|Phase 2,0.0935111854365872,0.9064888145634126
NCCS.O=C(O)C(O)C(O)C(=O)O,_CYSTEAMINE_BITARTRATE,ASTHMA,NCT03883984,Phase 1,0.41913807722017454,0.5808619227798255
CC(=O)C(=O)O,_PYRUVATE,PROSTATE CANCER,NCT02913131,Phase 1|Phase 2,0.6357991079309002,0.3642008920690998
CC(=O)C(=O)O,_PYRUVATE,BREAST CANCER,NCT03121989,Phase 1,0.5397799678006274,0.4602200321993727
CC(=O)C(=O)O,_PYRUVATE,GLIOMA,NCT03739411,Phase 1,0.4929791790978603,0.5070208209021397
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,_TERBUTALINE,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.24625169066671065,0.7537483093332891
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,_BUMETANIDE,PARKINSON'S DISEASE,NCT03899324,Phase 2,0.6114127912196032,0.3885872087803967
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.06488809951020175,0.935111900489798
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,_KETOTIFEN,FUNCTIONAL DYSPEPSIA,NCT02484248,Phase 3,0.05255927513464799,0.947440724865352
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,ST ELEVATION MYOCARDIAL INFARCTION,NCT03699215,Phase 3,0.24253414592552305,0.7574658540744771
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,_OXYMETAZOLINE,FECAL INCONTINENCE,NCT03529487,Phase 1,0.1305683452987345,0.8694316547012653
CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,_CYCLOPENTOLATE,CATARACT SURGERY,NCT03375996,,0.13918039017489525,0.8608196098251046
CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,_ZOPICLONE,"DEPRESSIVE DISORDER, MAJOR",NCT04451187,Phase 1,0.08510903111777303,0.9148909688822268
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,_GLYBURIDE,ACUTE SPINAL CORD INJURY,NCT02524379,Phase 1|Phase 2,0.257705857068282,0.7422941429317182
C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,_LISDEXAMFETAMINE,BULIMIA NERVOSA,NCT03397446,Phase 2,0.09909296181134726,0.9009070381886528
C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,_LISDEXAMFETAMINE,"OBESITY, MORBID",NCT03497169,,0.22987756441446394,0.7701224355855364
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,_LISDEXAMFETAMINE_DIMESYLATE,BULIMIA NERVOSA,NCT03397446,Phase 2,0.1646058040509189,0.8353941959490813
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,_LISDEXAMFETAMINE_DIMESYLATE,"OBESITY, MORBID",NCT03497169,,0.3625551290229373,0.6374448709770629
Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,_TOLTERODINE,PELVIC ORGAN PROLAPSE,NCT02599311,Phase 3,0.12479299083080825,0.8752070091691916
O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,_CLONAZEPAM,REM SLEEP BEHAVIOR DISORDER,NCT03255642,Not Applicable,0.026820506011656885,0.9731794939883432
CCOC(=O)c1ccc(N)cc1,_BENZOCAINE,OBESITY,NCT02537314,Phase 1,0.022407537369150327,0.9775924626308496
CN(C)CCC=C1c2ccccc2COc2ccccc21,_DOXEPIN,BREAST CANCER,NCT02447211,Phase 2,0.016448717297645778,0.983551282702354
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,_TERAZOSIN,PARKINSON'S DISEASE,NCT03905811,Phase 1|Phase 2,0.13990157050812735,0.8600984294918725
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,_TERAZOSIN,CAROTID ARTERY STENOSIS,NCT03195673,Phase 2,0.12381156483100365,0.8761884351689965
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,_VILDAGLIPTIN,MAJOR DEPRESSIVE DISORDER,NCT04410341,Phase 1|Phase 2,0.10660094429065683,0.8933990557093432
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,_FLUMAZENIL,PARKINSON'S DISEASE,NCT03462641,Phase 1|Phase 2,0.1673856259226033,0.8326143740773965
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,_DOMPERIDONE,GASTROPARESIS,NCT03810287,Early Phase 1,0.16660382481815172,0.8333961751818483
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,_ALBUTEROL_SULFATE,ASTHMA,NCT03847896,Phase 3,0.5352525420782193,0.4647474579217806
O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE_FUMARATE,POST TRAUMATIC STRESS DISORDER,NCT04280965,Early Phase 1,0.05569001837044176,0.944309981629558
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,PARKINSON'S DISEASE,NCT04164758,Phase 2,0.17031843355830595,0.8296815664416941
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,SCHIZOPHRENIA,NCT04531982,Phase 3,0.1913200998882402,0.8086799001117599
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,_TOMIVOSERTIB,BREAST CANCER,NCT04261218,Phase 1,0.6082581678546177,0.39174183214538216
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,_QUERCETIN,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT03989271,Phase 1|Phase 2,0.313464614390462,0.6865353856095381
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,_QUERCETIN,ALZHEIMER DISEASE,NCT04063124,Phase 1|Phase 2,0.4512283086247716,0.5487716913752285
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,_QUERCETIN,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.2740311619053333,0.7259688380946667
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,_SEMAGLUTIDE,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.1685247643708167,0.8314752356291832
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,_GLUCOSAMINE,KNEE OSTEOARTHRITIS,NCT04470336,Not Applicable,0.21436583538805126,0.7856341646119486
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,_FOSPHENYTOIN,TRIGEMINAL NEURALGIA,NCT03712254,,0.3183696531978832,0.6816303468021168
COC1=CC(=O)OC(/C=C/C2=CCCC=C2)C1,_KAVA,PHARMACOKINETICS,NCT03843502,Phase 1,0.339272632428144,0.6607273675718561
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,PAIN,NCT04313179,Not Applicable,0.15514872019500225,0.8448512798049979
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,_ETORICOXIB,MUSCULOSKELETAL PAIN,NCT04565600,Phase 2,0.010065384436900162,0.9899346155630996
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,_GENISTEIN,ALZHEIMER DISEASE,NCT01982578,Not Applicable,0.28309309672803284,0.716906903271967
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,_APREMILAST,ATOPIC DERMATITIS,NCT04306965,Phase 2,0.2760672979409542,0.7239327020590458
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,FRIEDREICH ATAXIA,NCT03933163,Phase 2,0.10191810559042012,0.8980818944095796
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,_RESVERATROL,KNEE OSTEOARTHRITIS,NCT02905799,Phase 3,0.06989387549407322,0.9301061245059266
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_TREHALOSE,BIPOLAR DISORDER|BIPOLAR DEPRESSION,NCT02800161,Phase 3,0.2552113944698077,0.7447886055301922
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_TREHALOSE,ACUTE CORONARY SYNDROME,NCT03700424,Phase 2,0.2446302576723905,0.7553697423276095
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,BINGE-EATING DISORDER,NCT04424745,Not Applicable,0.2455054288790775,0.7544945711209224
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,PAIN,NCT04132609,Not Applicable,0.2970800492747797,0.7029199507252204
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,OBSESSIVE COMPULSIVE DISORDER,NCT03921255,Not Applicable,0.24257977111929516,0.7574202288807049
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,MAJOR DEPRESSIVE DISORDER,NCT04137367,Not Applicable,0.19539913218348665,0.8046008678165134
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,ALCOHOL DRINKING,NCT04430543,Not Applicable,0.2823614350096164,0.7176385649903837
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,OBSTRUCTIVE SLEEP APNEA,NCT02666781,,0.4481090777363583,0.5518909222636417
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,NICOTINE DEPENDENCE,NCT03325777,Not Applicable,0.2662341793630733,0.7337658206369269
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,CANNABIS USE DISORDER,NCT03629990,Not Applicable,0.24257977111929516,0.7574202288807049
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,ANXIETY,NCT04245501,Not Applicable,0.29248541137215506,0.7075145886278449
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,PTSD,NCT04228133,Not Applicable,0.19539913218348665,0.8046008678165134
N[C@H](CO)C(=O)O,_D-SERINE,SCHIZOPHRENIA,NCT03702933,,0.5659075732810261,0.4340924267189738
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,_HESPERIDIN,METABOLIC SYNDROME,NCT03734874,Not Applicable,0.22704743969482555,0.7729525603051745
CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,_LOFEXIDINE,OPIOID USE DISORDER,NCT04056182,Phase 2,0.10452372358501044,0.8954762764149896
CC[C@@H]1[C@@H]2C[C@H](O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@H]3[C@H](C)CCC(=O)O)[C@@H]2[C@@H]1O,_OBETICHOLIC_ACID,OBESITY,NCT02532335,Phase 1,0.4585336142313924,0.5414663857686077
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,_SELICICLIB,CUSHING DISEASE,NCT03774446,Phase 2,0.6665617695210758,0.3334382304789241
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,_BAZEDOXIFENE,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT04002934,Phase 2,0.08871345912406832,0.9112865408759316
CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,_BAZEDOXIFENE_ACETATE,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",NCT04002934,Phase 2,0.1467550731399656,0.8532449268600343
O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,_FASUDIL,AMYOTROPHIC LATERAL SCLEROSIS,NCT03792490,Phase 2,0.6171589294440021,0.3828410705559979
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,_HYALURONIC_ACID,"PAIN, POSTOPERATIVE",NCT03814707,Not Applicable,0.022828075975474114,0.9771719240245258
O=[O+][O-],_OZONE,ISCHEMIC HEART DISEASE,NCT03660657,Phase 2|Phase 3,0.1681839367851217,0.8318160632148782
O=[O+][O-],_OZONE,KNEE OSTEOARTHRITIS,NCT04426721,Phase 3,0.1681839367851217,0.8318160632148782
Cc1c(O)c(=O)ccn1C,_DEFERIPRONE,AMYOTROPHIC LATERAL SCLEROSIS,NCT03293069,Phase 2|Phase 3,0.22099930824343286,0.7790006917565673
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,_TESAMORELIN,MILD COGNITIVE IMPAIRMENT,NCT02572323,Phase 2,0.6457549473494788,0.3542450526505214
C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,_EVOBRUTINIB,RELAPSING MULTIPLE SCLEROSIS,NCT04338061,Phase 3,0.7276320485531778,0.27236795144682197
C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2,_LINACLOTIDE,FUNCTIONAL CONSTIPATION,NCT04110145,Phase 2,0.2583886623873942,0.7416113376126059
NC[C@H](CC(=O)O)c1ccc(Cl)cc1,_ARBACLOFEN,AUTISM SPECTRUM DISORDER,NCT03887676,Phase 2,0.3813804651805511,0.618619534819449
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.1405775727624631,0.8594224272375367
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.3157301125663969,0.684269887433603
Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1,_SUVOREXANT,NICOTINE DEPENDENCE,NCT03999099,Phase 1,0.022883868983641826,0.977116131016358
COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O,_ELUXADOLINE,IRRITABLE BOWEL SYNDROME,NCT03339128,Phase 2,0.5800190441377586,0.4199809558622414
Cc1ncc(CO)c(CN)c1O,_PYRIDOXAMINE,"DIABETES MELLITUS, TYPE 2",NCT03778580,Not Applicable,0.2541427506642852,0.7458572493357145
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O,_DOTATATE,NEUROENDOCRINE TUMORS,NCT04318561,Phase 1|Phase 2,0.19844755657574734,0.8015524434242526
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,_RACLOPRIDE,MAJOR DEPRESSIVE DISORDER,NCT03026036,,0.27234795443688986,0.7276520455631099
O=N[O-],_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.29417848910847405,0.7058215108915258
O=N[O-],_NITRITE,OUT-OF-HOSPITAL CARDIAC ARREST,NCT03452917,Phase 2|Phase 3,0.29417848910847405,0.7058215108915258
O=N[O-].[Na+],_SODIUM_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.5452152637886916,0.4547847362113083
O=N[O-].[Na+],_SODIUM_NITRITE,OUT-OF-HOSPITAL CARDIAC ARREST,NCT03452917,Phase 2|Phase 3,0.5452152637886916,0.4547847362113083
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,_RELAMORELIN,GASTROPARESIS|DIABETES MELLITUS,NCT03420781,Phase 3,0.5210003091282231,0.4789996908717769
CCCCC1OC(=O)c2ccccc21,_BUTYLPHTHALIDE,CEREBRAL SMALL VESSEL DISEASE,NCT04078204,Not Applicable,0.041470840475237386,0.9585291595247624
CCCCC1OC(=O)c2ccccc21,_BUTYLPHTHALIDE,VASCULAR DEMENTIA,NCT03804229,Phase 3,0.11573885554600387,0.884261144453996
c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1,_CENTANAFADINE,ATTENTION DEFICIT HYPERACTIVITY DISORDER,NCT04398225,Phase 1,0.4960284476942051,0.5039715523057948
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,_IMETELSTAT,MYELODYSPLASTIC SYNDROME,NCT02598661,Phase 2|Phase 3,0.4566132939068321,0.5433867060931681
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,_VOXELOTOR,SICKLE CELL DISEASE,NCT04247594,Phase 2,0.3112217812228699,0.6887782187771302
CN1CC[C@]2(C)c3cc(OC(=O)Nc4ccccc4)ccc3N(C)[C@H]12,_POSIPHEN,ALZHEIMER DISEASE,NCT02925650,Phase 1|Phase 2,0.473604298783049,0.526395701216951
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,_AZD7325,FRAGILE X SYNDROME,NCT03140813,Phase 1,0.3457969646878018,0.6542030353121983
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,_AZD7325,AUTISM SPECTRUM DISORDER,NCT03678129,Not Applicable,0.3204637278784424,0.6795362721215576
O=C1/C(=C2\Nc3ccccc3C2=O)Nc2ccccc21,_INDIGO,COLONOSCOPY,NCT03250780,Not Applicable,0.5362810926235183,0.4637189073764818
CCCCCC1=CC(=O)C=C(OC)C1=O,_PRIMIN,STROKE,NCT03517657,Not Applicable,0.5932365182854781,0.40676348171452176
N[C@H](CC(=O)O)C(=O)O,_D-ASPARTATE,BRAIN INJURIES,NCT03228524,Early Phase 1,0.4601039887679342,0.5398960112320659
CC(/C=C/C=C(\C)C(=O)O)=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)O,_CROCETIN,"STROKE, ACUTE",NCT03763929,Phase 2,0.5010250113075623,0.4989749886924378
NC(=O)OCC(COC(N)=O)c1ccccc1,_FELBAMATE,EPILEPSY,NCT03196466,,0.33548381282164896,0.664516187178351
O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,_DANTROLENE,MULTIPLE SCLEROSIS,NCT03109288,Phase 1|Phase 2,0.4291257593741816,0.5708742406258185
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,MAJOR DEPRESSIVE DISORDER,NCT03739203,Phase 3,0.4431526781223708,0.5568473218776292
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,AUTISM SPECTRUM DISORDER,NCT04382885,Phase 1,0.4403451381274424,0.5596548618725575
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,SCHIZOPHRENIA,NCT03817502,Phase 3,0.43191145575086176,0.5680885442491382
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,_LASMIDITAN,MIGRAINE DISORDERS,NCT04396574,Phase 3,0.5249830984465751,0.47501690155342496
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.5080386548717665,0.4919613451282336
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,MENINGIOMA,NCT03631953,Phase 1,0.33879912688006386,0.6612008731199362
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,METASTATIC BREAST CANCER,NCT03238196,Phase 1,0.4958501979880477,0.5041498020119524
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12,_ERAVACYCLINE,BACTERIAL INFECTIONS,NCT03696550,Phase 1,0.3397168840802076,0.6602831159197926
N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,_RIMEGEPANT,TRIGEMINAL NEURALGIA,NCT03941834,Phase 2,0.5279161010374651,0.4720838989625349
CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N,_OZANIMOD,CROHN'S DISEASE,NCT03467958,Phase 3,0.4638472846627351,0.5361527153372649
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.3214076112741001,0.6785923887259001
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,CROHN'S DISEASE,NCT03345849,Phase 3,0.5069152185642858,0.4930847814357143
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ATOPIC DERMATITIS,NCT03569293,Phase 3,0.4996272766569347,0.5003727233430653
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,ULCERATIVE COLITIS,NCT03006068,Phase 3,0.5286914088525969,0.471308591147403
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,_UBROGEPANT,MIGRAINE DISORDERS,NCT04492020,Phase 3,0.4704569435175341,0.5295430564824658
